

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>7</sup> :</b><br><b>C12N 15/31, C07K 14/315, A61K 39/09, C07K 16/12</b>   | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 00/37648</b><br><b>(43) International Publication Date:</b> 29 June 2000 (29.06.00)  |
| <b>(21) International Application Number:</b> PCT/US99/30807<br><b>(22) International Filing Date:</b> 22 December 1999 (22.12.99)<br><br><b>(30) Priority Data:</b><br>60/113,794 22 December 1998 (22.12.98) US<br>60/114,730 31 December 1998 (31.12.98) US<br><br><b>(71) Applicant (for all designated States except US):</b> THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION [US/US]; 1534 White Avenue, Suite 403, Knoxville, TN 37996-1527 (US).<br><br><b>(72) Inventor; and</b><br><b>(75) Inventor/Applicant (for US only):</b> DALE, James [US/US]; Room BC-117, 1030 Jefferson Avenue, Memphis, TN 38104 (US).<br><br><b>(74) Agents:</b> MCMASTERS, David, D. et al.; Seed and Berry LLP, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).                |           | <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i><br><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| <b>(54) Title:</b> PROTECTIVE ANTIGEN OF GROUP A STREPTOCOCCI (SPA)  |           |  |
| <b>(57) Abstract</b><br><br>The present invention provides the discovery of a new Streptococcus protective antigen (herein designated Spa) which has been identified and isolated from Streptococci. Spa is a surface antigen distinct from M protein which evokes opsonic antibodies that are protective against multiple serotypes of streptococci. The invention further provides isolated Spa polypeptides, proteins, peptides, and antibodies against the same, as well as nucleic acids encoding Spa polypeptide and peptide antigens. Also provided are methods for identification and isolation of a Spa polypeptide, therapeutic compositions comprised of Spa antigens or antibodies and methods of their use in protecting an animal against a Streptococcus infection. |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |  |    |                          |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania                  | ES | Spain                                    | LS | Lesotho                                      | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                                  | LT | Lithuania                                    | SK | Slovakia                 |
| AT | Austria                  | FR | France                                   | LU | Luxembourg                                   | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                    | LV | Latvia                                       | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                           | MC | Monaco                                       | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                                  | MD | Republic of Moldova                          | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                    | MG | Madagascar                                   | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                   | MK | The former Yugoslav<br>Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                   |    |  | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                                  | ML | Mali   | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                                  | MN | Mongolia                                     | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                   | MR | Mauritania                                   | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                                  | MW | Malawi                                       | US | United States of America |
| CA | Canada                   | IT | Italy                                    | MX | Mexico                                       | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                    | NE | Niger  | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                    | NL | Netherlands                                  | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                               | NO | Norway                                       | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's<br>Republic of Korea | NZ | New Zealand                                  |    |                          |
| CM | Cameroon                 |    |  | PL | Poland                                       |    |                          |
| CN | China                    | KR | Republic of Korea                        | PT | Portugal                                     |    |                          |
| CU | Cuba                     | KZ | Kazakstan                                | RO | Romania                                      |    |                          |
| CZ | Czech Republic           | LC | Saint Lucia                              | RU | Russian Federation                           |    |                          |
| DE | Germany                  | LI | Liechtenstein                            | SD | Sudan  |    |                          |
| DK | Denmark                  | LK | Sri Lanka                                | SE | Sweden                                       |    |                          |
| EE | Estonia                  | LR | Liberia                                  | SG | Singapore                                    |    |                          |

## PROTECTIVE ANTIGEN OF GROUP A STREPTOCOCCI (SPA)

## TECHNICAL FIELD

The present invention relates to Streptococcal antigens, more particularly to polypeptide antigens and to nucleic acids encoding the same, which are useful for eliciting opsonic antibodies in an animal that are protective against infection by group A streptococci.

## BACKGROUND OF THE INVENTION

Group A streptococcal infections cause a wide array of clinical syndromes, ranging from uncomplicated pharyngitis and pyoderma to serious, invasive infections and toxic shock syndrome. Protection against infection is largely mediated by antibodies against the surface M protein of the organisms. M protein is an alpha-helical, coiled-coil molecule that extends from the surface with its hypervariable N-terminus exposed to the outside and the conserved C-terminus buried in the cytoplasm. The N-terminus contains type-specific epitopes that evoke bactericidal antibodies that correlate with protection against the homologous serotype. The *emm* gene is located in a regulon that is controlled by the upstream positive regulator *mga*. Depending on the serotype, the regulon may contain one, two or three *emm* and *emm*-like genes. In serotypes containing only one *emm* gene, deletion or interruption of the *emm* gene results in an avirulent organism that can no longer resist phagocytosis. In serotypes that express several *emm*-like genes, each may partially contribute to resistance to phagocytosis, but among the many defined surface proteins of group A Streptococci, only antibodies against the M protein have been shown to be opsonic.

Understanding the molecular basis of non-M protein mediated cross serotype protection would aid in providing therapeutic treatments for a variety of infections cause by group A streptococci. Type 18 Streptococci have been identified as an important serotype in the resurgence of acute rheumatic fever in Utah. In addition, Types 3 and 18, and to a lesser extent Type 28 Streptococci have all been implicated in the recent resurgence of serious Streptococcal diseases. Each of these diseases could be

potentially be prevented by vaccination with an antigen other than M protein, which is capable of eliciting a protective response across divergent serotypes.

Presently, there appears to be no showing in the art that group A streptococci (and all that follow-group A streptococci) express surface polypeptides or proteins containing opsonic epitopes not related to M protein. Providing polypeptides from Streptococci containing non-M protein antigens, especially those that have opsonic epitopes would enhance therapeutic tools available to protect against a variety of Streptococcal infections.

Therefore, there is a need in the art for the discovery and characterization of non-M protein antigens which are effective for protecting against such infections, especially antigens that are effective against multiple serotypes of group A Streptococci.

#### SUMMARY OF THE INVENTION

The present invention provides the discovery of a novel protective antigen isolated from a Streptococcus species that is distinct from M protein and that elicits opsonic antibodies that are effective against multiple serotypes of Streptococci. The novel antigen is a surface antigen of a group A Streptococci, which is herein designated as Spa (Streptococcal protective antigen).

In one aspect, the invention provides Spa polypeptides isolated from a Streptococcus species comprising a polypeptide having at least 50% amino acid sequence identity to SEQ. ID NO:2 or 5. In one embodiment, the Spa polypeptides are from a streptococcus which is a member of the species *Streptococcus pyogenes* (group A streptococci). Another embodiment includes an isolated Spa polypeptide from a group A, Type 18 Streptococci serotype. Still another embodiment is a Spa polypeptide comprising the amino acid sequence of SEQ. ID NOS: 2 or 5. Variants of this embodiment include amino acid sequences having conservative amino acid substitutions or those having at least 90% sequence identity to SEQ. ID NOS: 2 or 5.

In related embodiments, the invention provides any of the aforementioned isolated Spa polypeptides containing an opsonic epitope. In one

embodiment, the isolated polypeptides contain an opsonic epitope comprised of contiguous amino acids from a portion of an N-terminus of the polypeptide that is exposed on an outside surface of a cell when the polypeptide is expressed in the cell. In another embodiment, the isolated Spa polypeptide contains an opsonic epitope comprised of at least 8 contiguous amino acids of the N-terminus of the polypeptide. In another embodiment, the isolated Spa polypeptide contains an opsonic epitope comprised of at least 23 contiguous amino acids of the N-terminus of the polypeptide of SEQ. ID NOS: 2 or 5 or polypeptides having at least 50% identity thereto. In still another embodiment, the isolated Spa polypeptide includes the peptide of SEQ. ID NO: 3 or variants thereof that contain an opsonic epitope.

In a second aspect, the invention provides an immunogen for protecting an animal against a Streptococcus infection where the immunogen is comprised of any of the aforementioned Spa polypeptides. One embodiment of this aspect provides an immunogen for protecting an animal against a Streptococcus infection comprising a peptide that includes at least 8 contiguous amino acids from an N terminus of the aforementioned Spa polypeptides. Another embodiment provides an immunogen comprised of a peptide that includes at least 23 contiguous amino acids from an N terminus of the Spa polypeptide of SEQ. ID NOS: 2 or 5 or polypeptides having at least 50% identity thereto. In another embodiment, the immunogen includes the peptide of SEQ. ID NO: 3 or variants thereof that contain an opsonic epitope. In other embodiments, the aforementioned immunogens are linked to a carrier protein or provided as a fusion protein. Another aspect of any of aforementioned immunogens are that they provides cross-protection against multiple serotypes of Streptococci. In one embodiment the immunogens provide protection against serotypes of Streptococci which are group A serotypes. In another embodiment, the serotypes are selected from Type 3, Type 18 and Type 28 Streptococci.

In a third aspect, this invention provide antibodies that specifically bind to an epitope present on the aforementioned Spa polypeptides. One embodiment includes antibodies that bind to an epitope comprised of at least 8 contiguous amino acids of the N-terminus of the Spa polypeptide. Another embodiment includes

antibodies that bind to an epitope comprised of at least 23 contiguous amino acids of the N-terminus of the Spa polypeptide. In still another embodiment, the antibodies bind to a peptide according to SEQ. ID NO: 3 or variants thereof that contain an opsonic epitope. In still another embodiment, the invention provides the aforementioned  
5 antibodies which do not bind to an M protein of Streptococcus species.

In a fourth aspect, the invention provides an isolated nucleic acid molecule comprising a sequence that encodes the aforementioned Streptococcus Spa polypeptides or a complement of said nucleic acid molecule. In one embodiment, the isolated nucleic acid molecule is comprised of a sequence selected from SEQ. ID NOS:  
10 1, or 4, or 5 a complement or variants thereof. Variants of the nucleic acid sequences include variants selected from sequences that encode the polypeptide of SEQ. ID NOS: 2 or 5 which are degenerate to SEQ. ID NOS: 1 or 4 because of the genetic code; sequences that encode a polypeptide which has conservative amino acid substitutions to the polypeptide of SEQ. ID NOS: 2 or 5, or sequences that encode a polypeptide that is  
15 at least 50% identical to SEQ. ID NOS: 2 or 5. In still another embodiment, the invention provides an isolated nucleic acid molecule comprising a sequence that hybridizes to the aforementioned nucleic acid molecules under conditions of moderate or high stringency. Another embodiment includes isolated nucleic acid molecules comprising a sequence that encodes an opsonic epitope from a Spa polypeptide  
20 comprising a polypeptide having at least 50% amino acid sequence identity to SEQ. ID NOS: 2 or 5. A related aspect of the nucleic acid sequences provided herein include nucleic acid molecules encoding an opsonic epitope and further encoding a fusion polypeptide wherein the fusion polypeptide contains the opsonic epitope fused to at least one other peptide sequence. In one embodiment, the other peptide sequence  
25 includes a tag sequence that facilitates isolation of the fusion polypeptide from a cellular extract. In another embodiment, the other peptide sequence is a carrier protein.

A related embodiment to the aforementioned nucleic acid molecules includes a vector comprising those nucleic acid molecules operably linked to a promoter so that the vector expresses a polypeptide encoded by the isolated nucleic acid

when the vector is introduced into a host cell. In another embodiment, the invention provides a host cell carrying such a vector.

A fifth aspect of this invention provides a therapeutic composition for protecting an animal from a Streptococcus infection comprising a biologically acceptable diluent and an effective amount of an immunizing agent selected from the aforementioned polypeptides, peptides, immunogens, host cells and antibodies. In some embodiments, the therapeutic composition may include: a) a Spa polypeptide isolated from Streptococcus; b) an immunogen comprised of an opsonic epitope obtained from the Spa polypeptide; c) a host cell that expresses an opsonic epitope obtained from the Spa polypeptide; or d) an antibody that specifically binds to the Spa polypeptide. In another embodiment, the aforementioned immunizing agents may be conjugated to a polyvalent carrier.

A sixth related aspect of this invention includes a therapeutic method for protecting an animal against a Streptococcus infection comprising the step of administering to the animal the aforementioned therapeutic compositions wherein administering the therapeutic compositions elicits opsonic antibodies in the animal. In a preferred embodiment protection is provided against multiple serotypes of Streptococcus. In a related embodiment, the therapeutic composition is administered by at least one of oral administration, intranasal administration, parenteral (intramuscular, subcutaneous, or intravenous) vaccination. In another preferred embodiment, the therapeutic method is provided when the animal is a human.

In still another aspect, the present invention provides diagnostic compositions and methods for detecting infection by a Streptococcus species in a target sample. In one embodiment, primers derived from the nucleotide sequence of a Spa gene are used to amplify nucleic acids extracted from cells obtained from target sample. Typically, the extracted nucleic acid is DNA. Alternatively, the extracted nucleic acids contains mRNA. In one embodiment, diagnosis is performed by detecting a nucleic acid sequence amplified by PCR using primers provided in SEQ. ID NOS: 4 and 5. In other embodiments, primers are selected from any portion of a Spa gene or complement thereof containing at least 12 contiguous nucleotides, wherein the primers specifically

hybridize to a selected portion of the Spa gene. In still another embodiment, the invention provides probes useful in the diagnosis of a Streptococcus infection wherein the probes contain at least 12 contiguous nucleotides that specifically hybridize to a selected portion of the Spa gene.

5 In a different embodiments, the diagnostic compositions and methods of the present invention include antibodies that specifically bind to a Spa polypeptide. In one embodiment the antibodies are opsonic antibodies. In certain embodiments the antibodies are polyvalent antibodies while in other embodiments the antibodies are monoclonal antibodies. In still other embodiments, the antibodies are conjugated to a  
10 detectable signaling moiety. In other embodiments, the Spa antibodies are used in combination with other immunochemical reagents. In typical embodiments, the other immunochemical reagents form a complex with the Spa antibodies wherein the complex provides a detectable signal under conditions where a Spa polypeptide is bound to a Spa antibody.

15 In a related aspect, the invention provides diagnostic kits comprised of the aforementioned primers, probes or antibodies. In specific embodiments, the kits further contain reagents for detecting Spa nucleic acids which are amplified or which hybridize to the primers or probes provided herein. In another specific embodiment, the kits contain immunochemical reagents for detecting binding of Spa antibodies to Spa  
20 polypeptides isolated from a target sample.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (*e.g.*, plasmids, etc.), and are therefore incorporated by reference in  
25 their entirety.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a Western blot analysis of whole-cell extracts of M18 (lanes A, C, and E) and M18 $\Omega$  (lanes B, D, and F) reacted with rabbit antisera against rM18 (lanes A and B), SM18(1-30) (lanes C and D), and SM5(265-291) (lanes E and



F). Coomassie blue stained multiple proteins in extracts from both strains (M18, lane G and M18Ω, lane H).

Figure 2 illustrates identification of Spa in a crude pepsin extract of M18Ω. The extract was separated by preparative polyacrylamide gel electrophoresis and the entire gel was transferred to nitrocellulose paper. The ends of the paper were cut vertically and stained with Coomassie blue. The center section was cut into horizontal strips approximately 10-12 mm in width and each one is identified as a fraction number. These strips were cut into smaller pieces and used as to absorb opsonic antibodies from a rabbit antiserum against crude pep M18Ω. Opsonization assays were performed using the M18Ω strain, each absorbed antiserum, and antisera inhibited with 1 mg/ml of pep M18 or pep M18Ω. Percent inhibition was based on the level of opsonization achieved with the unabsorbed antiserum.

Figure 3 shows polyacrylamide gel electrophoresis of a purified fragment of Spa (lanes A and B) and Western blot analysis of the native protein extracted by phage lysin (lanes C and D). The crude pep M18Ω (lane A) and the purified Spa (lane B) were electrophoresed in a 10% polyacrylamide gel under reducing conditions and stained with Coomassie blue. The purified Spa migrated with an apparent molecular weight of 24 kDa. Western blot analysis was performed to identify the native Spa that was released from the cell wall of M18Ω by group C Streptococcal phage-associated lysin. The crude lysin extract contained multiple proteins that stained with Coomassie blue (lane C). Antiserum against the synthetic peptide of Spa reacted with a single protein in the extract with an apparent M.W. of 50kDa (lane D).

Figure 4 shows a partial DNA sequence of an isolated *spa* gene and a deduced amino acid sequence for a Spa polypeptide. The sequence has been submitted to GenBank and has the accession number AF086813.

Figure 5 (presented in Figures 5A, 5B and 5C) shows a full length DNA sequence according to SEQ ID NO:4 encoding a Spa polypeptide. A start codon begins at position 145, a signal peptide is encoded by positions 145-255 and a mature protein begins at position 256.

Figure 6 shows an amino acid sequence for a full length Spa polypeptide according to SEQ ID NO:5. A signal peptide at positions 1-37 is underlined.

## DETAILED DESCRIPTION OF THE INVENTION

### DEFINITIONS

5 Prior to setting forth the Invention in detail, it may be helpful to an understanding thereof to set forth definitions of certain terms and to list and to define the abbreviations that will be used hereinafter.

“Nucleic acid” or “nucleic acid molecule” refers to any of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), oligonucleotides, fragments  
10 generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acids can be composed of monomers that are naturally-occurring nucleotides (such as deoxyribonucleotides and ribonucleotides), or analogs of naturally-occurring nucleotides (*e.g.*,  $\alpha$ -enantiomeric forms of naturally-occurring nucleotides), or a  
15 combination of both. Modified nucleotides can have modifications in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically  
20 similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analog  
of phosphodiester linkages include phosphorothioate, phosphorodithioate,  
25 phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like. The term “nucleic acid” also includes so-called “peptide nucleic acids,” which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.

An "isolated nucleic acid molecule" is a molecule that is not integrated in the genomic DNA of an organism. For example, a DNA molecule that encodes a Spa polypeptide that has been separated from the genomic DNA of a Streptococcus cell is an isolated DNA molecule. Another example of an isolated nucleic acid molecule is a  
5 chemically-synthesized nucleic acid molecule that is not integrated in the genome of an organism. The isolated nucleic acid molecule may be genomic DNA, cDNA, RNA, or composed at least in part of nucleic acid analogs.

An "isolated" polypeptide" is a polypeptide that has been removed by at least one step from its original environment. For example, a naturally occurring protein  
10 is isolated if it is separated from some or all of the coexisting material in the natural system such as carbohydrate, lipid, or other proteinaceous impurities associated with the polypeptide in nature. Within certain embodiments, a particular protein preparation contains an isolated polypeptide if it appears nominally as a single band on SDS-PAGE gel with Coomassie Blue staining.

15 "Promoter" is a nucleotide sequence that directs the transcription of a structural gene. Typically, a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a structural gene. If a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a  
20 constitutive promoter.

"Vector" refers to an assembly which is capable of directing the expression of desired protein. The vector must include transcriptional promoter elements which are operably linked to the genes of interest. The vector may be composed of either deoxyribonucleic acids ("DNA"), ribonucleic acids ("RNA"), or a  
25 combination of the two (*e.g.*, a DNA-RNA chimeric). Optionally, the vector may include a polyadenylation sequence, one or more restriction sites, as well as one or more selectable markers such as neomycin phosphotransferase or hygromycin phosphotransferase. Additionally, depending on the host cell chosen and the vector employed, other genetic elements such as an origin of replication, additional nucleic

acid restriction sites, enhancers, sequences conferring inducibility of transcription, and selectable markers, may also be incorporated into the vectors described herein.

“Cloning vector” refers to nucleic acid molecules, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell. Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign nucleotide sequences can be inserted in a determinable fashion without loss of an essential biological function of the vector, as well as nucleotide sequences encoding a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.

“Expression vector” refers to a nucleic acid molecule encoding a gene that is expressed in a host cell. Typically, gene expression is placed under the control of a promoter, and optionally, under the control of at least one regulatory element. Such a gene is said to be “operably linked to” the promoter. Similarly, a regulatory element and a promoter are operably linked if the regulatory element modulates the activity of the promoter.

“Recombinant host” refers to any prokaryotic or eukaryotic cell that contains either a cloning vector or expression vector. This term also includes those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell.

In eukaryotes, RNA polymerase II catalyzes the transcription of a structural gene to produce mRNA. A nucleic acid molecule can be designed to contain an RNA polymerase II template in which the RNA transcript has a sequence that is complementary to that of a specific mRNA. The RNA transcript is termed an “anti-sense RNA” and a nucleic acid molecule that encodes the anti-sense RNA is termed an “anti-sense gene.” Anti-sense RNA molecules are capable of binding to mRNA molecules, resulting in an inhibition of mRNA translation.

“Moderate or stringent hybridization conditions” are conditions of hybridization of a probe nucleotide sequence to a target nucleotide sequence wherein hybridization will only be readily detectable when a portion of the target sequence is

substantially similar to the complement of the probe sequence. Hybridization conditions vary with probe size as well as with temperature, time and salt concentration in a manner known to those of ordinary skill in the art. For example, moderate hybridization conditions for a 50 nucleotide probe would include hybridization  
5 overnight a buffer containing 5xSSPE (1xSSPE = 180 mM sodium chloride, 10 mM sodium phosphate, 1 mM EDTA (pH 7.7), 5xDenhardt's solution (100xDenhardt's = 2% (w/v) bovine serum albumin, 2% (w/v) Ficoll, 2% (w/v) polyvinylpyrrolidone) and 0.5% SDS incubated overnight at 55-60°C. Post-hybridization washes at moderate stringency are typically performed in 0.5xSSC (1xSSC = 150 mM sodium chloride, 15  
10 mM trisodium citrate) or in 0.5xSSPE at 55-60°C. Stringent hybridization conditions typically would include 2x SSPE overnight at 42°C, in the presence of 50% formamide followed by one or more washes in 0.1-0.2x SSC and 0.1% SDS at 65°C for 30 minutes or more.

"Percent identity" or "% identity" with reference to a subject polypeptide  
15 or peptide sequence is the percentage value returned by comparing the whole of the subject polypeptide sequence to a test sequence using a computer implemented algorithm, typically with default parameters. Sequence comparisons can be performed using any standard software program such as BLAST, tBLAST or MEGALIGN mentioned above. Still others include those provided in the LASERGENE  
20 bioinformatics computing suite, which is produced by DNASTAR (Madison, Wisconsin). Reference for algorithms such as ALIGN or BLAST may be found for example, in Altschul, *J. Mol. Biol.* 219:555-565, 1991; Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915-10919, 1992) BLAST is available at the NCBI website (<http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST>). Other methods for comparing two  
25 nucleotide or amino acid sequences by determining optimal alignment are well-known to those of skill in the art (see, for example, Peruski and Peruski, *The Internet and the New Biology: Tools for Genomic and Molecular Research* (ASM Press, Inc. 1997), Wu et al. (eds.), "Information Superhighway and Computer Databases of Nucleic Acids and Proteins," in *Methods in Gene Biotechnology*, pages 123-151 (CRC Press, Inc. 1997),

and Bishop (ed.), Guide to Human Genome Computing, 2nd Edition (Academic Press, Inc. 1998)).

“Spa” or “Spa polypeptide” should be understood to include any polypeptide, or nucleic acid encoding a polypeptide having at least 50%, 60%, 70%,  
5 80%, 90%, or 95% amino acid identity to the polypeptides provided herein as SEQ ID NO:2, or 5.

“Specifically binds” means an antibody is able to selectively bind a peptide encoded by a *spa* gene of this invention. Such an antibody generally associates with a Spa polypeptide with an affinity constant ( $K_a$ ) of at least  $10^4$ , preferably at least  
10  $10^5$ , more preferably at least  $10^6$ , still more preferably at least  $10^7$  and most preferably at least  $10^8$ . Affinity constants may be determined by one of ordinary skill in the art using well known techniques (*see* Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949).

Abbreviations: YAC, yeast artificial chromosome; PCR, polymerase chain reaction; RT-PCR, PCR process in which RNA is first transcribed into DNA at  
15 the first step using reverse transcriptase (RT); cDNA, any DNA made by copying an RNA sequence into DNA form.

This invention provides a novel family of polypeptides isolated from a Streptococci species that are distinct from M protein and which provide antigens that elicit opsonic antibodies in an animal. These novel polypeptides, herein designated as  
20 Spa (Streptococcal protective antigens). contain opsonic epitopes that cross react with multiple serotypes of Streptococci. Also provided are nucleic acid molecules (SEQ. ID NOS: 1 and 4) which encode representative Spa polypeptides (SEQ. ID NOS: 2 and 5). SEQ ID NO:2 encodes a 112 residue polypeptide that is a part of the N-terminus of a mature Spa polypeptide. Also provided is a 23 amino acid peptide sequence (SEQ. ID  
25 NO: 3) comprising a portion of an N-terminus of a Spa polypeptide which contains an opsonic epitope. The polypeptides of SEQ. ID NOS: 2 and 3 are therefore part of a larger protein of about 50 kD encoded by a Streptococcus gene herein designated as *spa*. SEQ ID NO:4 is a full-length *spa* gene encoding the full-length pro-protein of SEQ ID NO:5. SEQ ID NOS: 2 and 3 are part of the mature protein and corresponds to  
30 position 44 of SEQ ID NO:5. The invention also encompasses variants of the nucleic

acid represented by SEQ. ID NOS: 1 and 4, and the polypeptides represented by SEQ. ID NOS: 2, 3 or 5 which are further described hereafter. Vectors and host cells carrying nucleic acids encoding Spa or opsonic epitopes of Spa are also provided by the present invention.

5           The invention further includes immunogens comprised of Spa polypeptides and/or peptides comprised of contiguous amino acids from the N-terminus of a Spa polypeptide. Also included in this invention are antibodies that specifically bind to a Spa polypeptide or to antigens contained therein. The polypeptides, antigens, host cells expressing opsonic epitopes and antibodies that specifically bind thereto can  
10 each serve as immunizing agents in therapeutic compositions for protecting an animal from infection by multiple serotypes of Streptococci. Accordingly, this invention further encompasses such therapeutic compositions and methods of their use to protect an animal against a Streptococcus infection.

#### I. Polypeptides

15           The identification of the novel polypeptide from Streptococci was facilitated by production of an M-negative mutant of a Streptococcal strain that is fully virulent when compared to the parent strain. Production of a fully virulent M-negative mutant is a surprising result in light of prior teaching, such as provided for example by Moses, et al. who showed that an M-negative mutant of an M18 strain (87-282) had  
20 reduced virulence relative to the parent. The present invention demonstrates that production of an M-negative mutant provides a Streptococcal strain that maintains virulence and which exposes the presence of a non-M polypeptide displaying an opsonic epitope of a surface protein. As used herein, an "opsonic epitope" is that peptide or polypeptide portion of a protein which forms an antigen that elicits the  
25 production of, and binds to, opsonic antibodies evoked by immunizing an animal with a host cell containing the antigen. A "surface protein" is protein having a portion of its amino acid sequence displayed on the outer surface of a host cell which contains the protein. "Opsonic antibodies" has the meaning commonly understood by those of

ordinary skill in the art as antibodies which facilitates phagocytic activity against a particle, such as a host cell, that contains the antigen.

One way to produce an M-negative mutant is by inactivation of an *emm* gene encoding an M protein in a Streptococcal strain. Suitable strains include any pathogenic Streptococci. In one embodiment of this invention, a group A Type 18 Streptococcus (designated M18) is used. Many methods are known in the art for inactivation of a bacterial gene are suitable for the practice of this invention. In one method exemplified herein, a  $\Omega$  interposon element is introduced into the chromosome of a Streptococcal species to inactivate an *emm* gene present in a Type 18 Streptococcus serotype (*emm18*). One way to accomplish this is to first ligate a  $\Omega$  interposon element into the coding sequence of an *emm18* gene that has been cloned into a first vector so as to obtain a second vector containing an *emm18* which is inactivated by insertion of the  $\Omega$  element. This second vector is then used to transform a parent strain so that the inactivated *emm18* recombines with and replaces the native *emm18* gene present on the chromosome of the parent strain.

Insertionally inactivated strains can be screened for the presence of the inactivated *emm18* gene by southern blotting using the  $\Omega$  interposon element as a probe in combination with a probe for the *emm18* gene. Inactivation of the *emm18* gene can be confirmed by showing absence of expressed M protein by any method for detecting the protein such as for example, immunoblotting an extract using an antibody specific for the M protein. Figure 1 illustrates western blotting to determine the absence of expressed M protein in one M negative mutant (M18 $\Omega$ , described hereafter) using antisera prepared against each of; a native M protein (rM18) from a Type 18 Streptococcus; a 30 amino acid N-terminal peptide of the M18 protein, (SM18(1-30)); and an internal fragment from a Type 5 Streptococcus M protein (SM5(265-291)). (see also Example 1).

One purpose of making an M-negative Streptococcus mutant is to facilitate detection of non-M protein surface antigens which contain opsonic epitopes. An M-negative mutant suitable for identifying a Spa antigen preferably exhibits continued virulence in a mammalian system because non-virulent strains are less likely



to elicit opsonic antibodies. Virulence of an M-negative mutant may be tested by several methods known in the art. One method is grow the strain in mammalian blood and to score virulence by the number of generations of growth obtained in the blood culture. Typically, a virulent strain will grow for at least 4 generations after three hours of culture in mammalian blood. Typically, a test for virulence in blood uses blood obtained from an animal for which protection against Streptococcal infection is sought. In one practice of this invention, an M18 parent strain used to produce the M-negative mutant M18 $\Omega$  grew for 8 generations after a three hour rotation in human blood. The M18 $\Omega$  mutant showed similar virulence by growing for 7.5 generations under the same conditions. (See Example 1).

Another method for assessing virulence is by an intraperitoneal challenge infection. Briefly, this method determines the does of bacterial particles necessary to be lethal in a test animal, usually a mouse. Virulence is scored by calculating the number of bacteria that is lethal to 50% of test animals after intraperitoneal injection (LD50). Typically, a virulent strain will have an LD50 of less than  $10^6$  in a mouse. For example, the M18 parent strain discussed above had an LD50 of  $0.73 \times 10^5$  while the M18 $\Omega$  mutant had an LD50 of  $1.26 \times 10^5$ . Optionally, the lethality of the mutant bacteria can be confirmed by recovering live bacteria from the spleens of test animals which succumb to the injection and testing for the presence of identifying characteristics of the mutant, such as for example, drug resistance or maintenance of the M-negative phenotype.

Once a virulent M-negative Streptococcus mutant has been obtained, the presence of a Spa polypeptide can be initially assessed by scoring for the presence of opsonizing epitopes on the surface of the mutant bacteria. The ordinarily skilled artisan will recognize a variety of *in vivo* and *in vitro* methods of testing for the presence of opsonizing epitopes. One method is to raise antisera against a crude surface peptide fraction (pep) released from the surface of bacterial particles after treating bacterial particles with a protease, and then to use the antisera in an *in-vitro* opsonization assay.

Many proteases known in the art are suitable for the preparation of a crude surface peptide fraction from the surface of bacteria. Usually a protease which

cleaves many different peptide linkages, such as for example pepsin, is incubated with a bacterial particles under reaction conditions that are suboptimal for the activity of the protease and/or with an amount of protease selected to yield a mixture enriched with larger rather than smaller polypeptides. Guidance for reaction conditions useful for releasing surface peptides from Streptococci particles may be found in part by the disclosure provided herein. (See Examples 3 and 4). Antisera against the crude surface peptide fraction may be raised in several species, typically mammals and, most typically rabbits. Methods of raising antisera against a peptide fraction are well known in the art and some of these are described hereafter.

10           An example *in vitro* opsonization assay useful in the practice of this invention is an opsonophagocytosis assay which detects phagocytosis facilitated by the presence of opsonizing antibodies present in a test antisera. Briefly, the assay measures the amount of phagocytosis of selected bacterial particles after preincubating the particles in the presence or absence of antisera raised against a sample of antigens  
15           obtained from the test bacteria. Preincubation with the antisera coats the particles with reactive antibodies, some of which will be opsonic antibodies elicited from opsonic epitopes present on the surface of the bacterial particles. Preincubated coated particles are then mixed with whole blood from an animal, typically a mammal for which opsonic protection is to be sought (*e.g.*, a human) to determine the percentage of  
20           neutrophils that associate with the bacterial particles which is a measure of phagocytic activity facilitated by opsonic antibodies. Antisera containing opsonic antibodies induce a higher percentage of neutrophils associated with the selected bacteria than does antisera lacking opsonic antibodies. In a variation of this test, the bactericidal activity of antisera can be tested by incubating the antisera with fewer bacterial  
25           particles, incubating in blood for a longer period of time and then plating the mixture on a culture medium to score for viable bacteria. The presence of opsonic antibodies in the antisera increase the number of bacteria destroyed by phagocytosis and therefore lowers the number of colony forming units (CFUs) detected on the plate culture.

          One advantage of these assays is that bacteria particles can be selected to  
30           score for serotype and strain specificity of opsonic epitopes. Thus, antisera raised

against crude surface peptides obtained from one serotype may be tested for the ability to provide opsonic protection against other serotypes by scoring for opsonophagocytosis or bactericidal activity against the other serotypes. In addition, the presence of a novel opsonic polypeptide, such as the Spa antigen of the present invention, can be detected by comparing the ability of different antisera raised against different surface antigen preparations to provide opsonic protection against different strains. For example, in one embodiment of this invention, antisera raised against crude surface peptides obtained from the M18 parent strain provided opsonic protection against both the parent and the M18 $\Omega$  mutant, however, antisera raised against purified M protein of the parent (M18 protein) or an N-terminal fragment thereof only provided protection against the parent and not the mutant strain. (See Example 3) This indicates for the first time, that a Streptococcus species contains opsonic epitopes on its surface that differ from the previously known opsonic epitopes of the M protein class.

In a similar fashion, antisera raised against crude surface peptides from the M18 $\Omega$  mutant were shown to provide opsonic protection against not only itself, but against the M18 parent and other Streptococcal serotypes as well. In one example, opsonic protection was provided against at least three serotypes of group A Streptococci including Type 3, Type 18 and Type 28. This indicates the mutant displays a novel opsonic epitope other than M protein which is capable of providing opsonic protection across multiple Streptococci serotypes. Thus, although the parent, the mutant and other serotypes display the novel opsonic epitope (Spa) this epitope is readily shown to be distinct from M protein by showing the M negative mutant expressed the epitope even while M protein is not expressed. Identification of a virulent, M-negative Streptococcus mutant provides a first step in a general method for the identification and isolation of the Spa polypeptides and antigens of the present invention.

Identification of the polypeptide containing a Spa antigen is accomplished by separating the surface polypeptides of a Streptococcus and identifying a fraction that possesses the opsonic epitope indicative of the Spa antigen. In one method, the surface polypeptide to be separated is comprised of the crude surface peptide mixture obtained by protease treatment of an M-negative Streptococcus mutant

shown to display an opsonic epitope other than M protein. Preferably, separation is performed to isolate the Spa polypeptide from other peptides present in the crude surface peptide mixture. One skilled in the art is able to envision numerous protocols for separating a crude surface peptide mixture including but not limited to a wide spectrum of electrophoresis and chromatography techniques particularly designed for separating polypeptides.

In a typical practice of this invention, a combination of polyacrylamide gel electrophoresis, antibody binding and opsonization inhibition assays are used to separate and identify Spa polypeptides containing opsonic epitopes. An example of use of this protocol is illustrated in Figure 2. Briefly, a crude surface peptide mixture is separated on a preparative 10% SDS polyacrylamide gel and then immunoblotted onto nitrocellulose paper or other suitable blotting substrate. The nitrocellulose paper is cut into strips containing different fractions of the separated polypeptides and incubated with antisera prepared against the crude surface peptide mixture to absorb antibodies that bind to the separated polypeptides. The absorbed antisera are then used in an opsonization assay and compared to the results obtained with unabsorbed antisera. Opsonic polypeptides present on the nitrocellulose strips will absorb opsonic antibodies from the test antisera so that the residual antisera will show reduced activity (inhibition) in an opsonization assay in comparison to unabsorbed antisera. In a typical practice, a duplicate immunoblot is subjected to ordinary western blotting to confirm the presence of immunoreactive polypeptides. Additionally, a duplicate polyacrylamide gel can be prepared to aid in purification of polypeptides shown to contain opsonic epitopes by the opsonizations inhibition assays

In one practice of the invention, the identified Spa polypeptide is isolated and purified by any polypeptide purification techniques known in the art. As used herein, to "isolate" means to take any step to separate a species from a milieu in which it naturally occurs, and to "purify" means to isolate a fraction wherein the desired species represents 50%-100% of all extracted polypeptides present in the fraction. For further characterization of Spa, it is preferred that the Spa polypeptide comprise at least 90% and more preferably at least 95% of polypeptides in the purified fraction. Typical

isolation steps useful in the practice of this invention include, but are not limited to, ammonium sulfate precipitation, polyacrylamide gel electrophoresis and HPLC. These techniques are suitable to provide a Spa polypeptide of sufficient quantity and purity to obtain an N-terminal sequence and to raise specific antibodies in a mammal such as a  
5 rabbit.

In one embodiment, a Spa polypeptide present in an group A, Type 18 Streptococcus was identified and purified using the aforementioned protocols with antisera obtained from the M18Ω mutant described above. The polypeptide was purified from a crude surface peptide fraction obtained from the mutant by using  
10 precipitation in 60% saturated ammonium sulfate, followed by dialysis, lyophilization, and preparative polyacrylamide gel electrophoresis. Figure 3(A,B) shows that the isolated polypeptide is estimated to have a size of 24 kD as determined by analytical polyacrylamide gel electrophoresis. Figure 3(C,D) shows a western blot analysis of native proteins released from the cell wall of M18Ω by phage associated lysin C and  
15 illustrates that the 24 kD Spa polypeptide is part of a larger native protein having an estimated size of 50 kD.

In another embodiment, a Spa polypeptide isolated according to the present invention is used to identify and isolate peptide antigens containing opsonic epitopes comprised of contiguous amino acids present on the N-terminus of a Spa  
20 polypeptide. One example is provided by SEQ. ID NO: 3. As used herein, "contiguous amino acids" is a sequence of amino acids which are identical to, or conservative variants of, a precise sequence of amino acids present on a Spa polypeptide. The Spa polypeptides of the present invention are isolated from a cell that expresses the polypeptide and which has a portion of the amino acid sequence of the polypeptide  
25 exposed on the outside surface of the cell. "Exposed on the outer surface" means the polypeptide has a portion extended through the outer membrane of the cell which is accessible to a proteases and/or to interaction with the major histocompatibility complex of an animal without having to rupture the cell. As used herein, the "N-terminus" is a sequence of about 240 amino acids or less that is present at or near the N  
30 terminal of a polypeptide that can be obtained after proteolytic cleavage of polypeptides

exposed on the surface of a cell. Therefore, the term includes an N-terminus of a proteolytic fragment as well as an N-terminus of a native protein when the N-terminus of the native protein is exposed on the outer surface of a cell.

The N terminus of the Spa polypeptides of the present invention undoubtedly contains shorter peptide sequences that form opsonic epitopes because it is highly unlikely that opsonic antibodies recognize an epitope requiring the entire sequence of a polypeptide exposed to the outer surface of a cell. It is well known in the art that an epitope may consist of peptide sequence as small as 8 amino acids which is generally considered by those skilled in the art to be the lower size limit for a peptide to be capable of forming an epitope that can interact with the major histocompatibility complex (MHC). Therefore, another aspect of this invention includes polypeptides and peptides containing opsonic epitopes comprised of at least 8 contiguous amino acids from the N-terminus of an isolated Spa polypeptide. Identification of an opsonic amino acid sequence on the Spa polypeptides of the present invention may be accomplished by a variety of methods.

One method is to use chemical degradation of Spa to obtain peptide fragments and to test those peptide fragments or to synthetic peptides containing contiguous amino acids derived therefrom, for the presence of opsonic epitopes. In one practice of this invention, Edman degradation of the purified Spa polypeptide is used to provide a precise amino acid sequence for the N-terminus of the isolated polypeptide. In another embodiment, Edman degradation is used to provide a precise amino acid sequence of an internal fragment prepared by enzymatic or chemical digestion of the isolated polypeptide. For example, Edman degradation of the Spa polypeptide isolated from the M18Ω mutant described above provided two amino acid sequences: a first sequence of 23 amino acids comprising a portion of the N-terminus of the isolated polypeptide and a second sequence of 10 amino acids comprising a portion of an N-terminus of an internal peptide fragment that was isolated after LysC digestion of the polypeptide. The sequence of the 23 amino acid N-terminus is provided in SEQ. ID NO: 3 and shown in Example 4 along with the sequence of the internal fragment. While not wishing to be bound by speculation, it is believed that SEQ. ID NO: 3

represents the N-terminus of the native Spa protein, however, the possibility that the native Spa protein contains additional amino acids at the N-terminus cannot be excluded. A comparison to SEQ ID NO:5 shows that the native protein is processed from a preprotein by removal of a residue signal sequence.

5                   When smaller peptide fragments or sequences are isolated from a Spa polypeptide, the isolated peptide fragments or sequences can be identified as containing an opsonic epitope by modification of the methods described above for identifying an opsonic polypeptide. The only modification required is use of a separation system suitable for the separation of smaller peptides. High percentage polyacrylamide gels  
10 and HPLC techniques are particularly suited for separating smaller peptides and such techniques are readily accessible to those skilled in the art. Alternatively, synthetic peptides can be made which are contiguous with the amino acid sequences deduced by Edman degradation. Therefore, embodiments of the present invention include peptides containing opsonic epitopes comprised of at least 8 contiguous amino acids of a Spa  
15 polypeptide.

                  In one embodiment, a peptide containing 23 contiguous amino acids of SEQ. ID NO: 3 which represents the N terminus of an isolated Spa polypeptide is chemically synthesized. That peptide, herein designated *spa18*(1-23) is shown to be opsonic by first chemically coupling it to a suitable carrier such as KLH and using it to  
20 raise antisera in rabbits. Another antiserum is made against the intact Spa polypeptide for comparison. These antisera are then used to show cross reactivity with antisera prepared from crude surface peptides obtained from an M-negative mutant such as M18 $\Omega$  and to further show the presence of opsonic epitopes using the opsonization assays described above. Results demonstrate that the 23 amino acid peptide of the N  
25 terminus of the Spa polypeptide contains an opsonic epitope having a similar opsonizing capacity as that obtained from the whole isolated polypeptide and from the crude surface peptide fraction. Western blotting also shows that antisera to the purified protein and the 23 amino acid peptide does not bind to an M protein such as M18. Results further show that the 23 amino acid peptide and isolated Spa polypeptide  
30 produce antisera capable of providing opsonic protection against the parent M18 strain,

the mutant strain and other serotypes of Streptococcus, while antisera prepared against M protein from the parent strain is only able to provide opsonic protection against the parent strain. (See Examples 5 and 6.)

While determining a precise amino acid sequence for an isolated Spa polypeptide or peptide epitopes contained therein is a preferred practice of this invention, it is not necessary to structurally define the isolated polypeptide at the sequence level to obtain the Spa polypeptides provided herein. The aforementioned description provides a method useful for isolating Spa polypeptides from any Streptococcus source, particularly from group A Streptococci. As is evident from the foregoing description, a Spa polypeptide is a polypeptide product having particular functional characteristics that fulfill requirements of the method and which are thereby isolated by practice of the method. To summarize, a Spa polypeptide is a polypeptide product obtained from a Streptococcus species which is displayed on the outer surface of a Streptococcus bacterium, and which contains antigenic epitopes other than the epitopes contained on an M protein. These epitopes represent opsonic antigens that do not cross react with antisera prepared against M-protein and which are capable of providing opsonic protection against multiple serotypes of Streptococci. These characteristics are found in a polypeptide isolated according to the practices described in this invention.

More particularly, this invention provides a method for identifying and isolating a non M protein Spa polypeptide of a Streptococcus species that elicits opsonic antibodies protective against multiple serotypes of Streptococci. The method includes the steps 1) producing a virulent mutant of the Streptococcus species that does not express an M protein; 2) obtaining antisera against a crude surface polypeptide fraction obtained from the mutant; 3) determining that the antisera contains opsonic antibodies that do not cross react with M protein and which provide opsonic protection against the mutant; 4) separating polypeptides in the extract to obtain isolated polypeptide fractions; 5) screening the isolated polypeptide fractions with antisera containing opsonic antibodies to identify Spa polypeptides that contain opsonic epitopes; 6) purifying the polypeptide identified as having opsonic epitopes; and 7)



testing the purified polypeptides to determine that they elicit opsonic antibodies that are protective against multiple serotypes of Streptococci.

Therefore, another embodiment of this invention includes Spa polypeptides isolated according to this method. The skilled artisan will immediately  
5 recognize that this method enables the isolation of a variety of Spa polypeptides from a variety of Streptococcus species. Thus, for example, while the Spa polypeptide isolated from an M18 mutant exemplified in one practice of this invention is protective against at least three serotypes of Streptococci (See Example 6) other Spa polypeptides isolated from other Streptococci can be isolated that are protective against other serotypes of  
10 Streptococci.

## II. Nucleic Acids

Another aspect of the present invention is isolated nucleic acid molecules comprising a sequence that encodes a Streptococcus Spa polypeptide. This aspect of the invention pertains to isolated nucleic sequences encoding a Spa  
15 polypeptide (*i.e.* a *spa* gene) as well as those sequences readily derived from isolated nucleic molecules such as for example complementary sequences, reverse sequences and complements of reverse of sequences.

In one embodiment, the isolated nucleic acid molecule is comprised of a sequence selected from SEQ. ID NOS: 1 or 4, a complement of SEQ. ID NOS: 1 or 4 or  
20 variants thereof. Variants of the nucleic acid sequences include variants selected from sequences that encode the polypeptide of SEQ. ID NOS: 2 or 5 which are degenerate to SEQ. ID NOS: 1 or 5 because of the genetic code; sequences that encode a polypeptide which has conservative amino acid substitutions to the polypeptide of SEQ. ID NOS: 2 or 5, or sequence that encode a polypeptide that is at least 50% identical to SEQ. ID  
25 NO: 2 or 5. In still another embodiment, the invention provides an isolated nucleic acid molecule comprising a sequence that hybridizes to the aforementioned nucleic acid molecules under conditions of high stringency. Another embodiment includes isolated nucleic acid molecules comprising a sequence that encodes an opsonic epitope from a Spa polypeptide. A related aspect of the nucleic acid sequences provided herein include

nucleic acid molecules encoding an opsonic epitope and further encoding a fusion polypeptide wherein the fusion polypeptide contains the opsonic epitope fused to at least one other polypeptide sequence. In one embodiment, the other peptide sequence includes a tag sequence that facilitates isolation of the fusion polypeptide from a cellular extract. In another embodiment the other peptide sequence is a carrier protein.

A related embodiment to the aforementioned nucleic acid molecules includes a vector comprising those nucleic acid molecules operably linked to a promoter so that the vector expresses a polypeptide encoded by the isolated nucleic acid when the vector is introduced into a host cell. In another embodiment, the invention provides a host cell carrying such a vector.

As used herein, a *spa* gene is a Streptococcus gene or nucleic acid variant thereof, that encodes at least 100 amino acids of a Spa polypeptide including for example, the isolated nucleic acid of SEQ. ID NOS: 1 or 4, a nucleic acid that encodes a 24kDa Spa polypeptide or a nucleic acid that encodes a native Spa protein of about 50 kDa. One example of part of a *spa* gene is set forth in Figure 4, and in SEQ ID NOS:1-2 which provides a nucleotide and amino acid sequence from one *spa* gene isolated from a Type 18 Streptococcus. Another example is set forth in Figures 5 and 6 that shows full-length nucleic acid and amino acid sequences according to SEQ ID NOS: 4 and 5, respectively. These represent full-length *spa* sequences and that include a signal peptide of 37 residues that is cleaved to produce a mature *spa* protein, as indicated.

Another aspect of the isolated *spa* nucleic acids of this invention includes fragments of isolated sequences. As used herein, a "fragment" of an isolated *spa* gene includes any nucleic acid sequence comprising at least 12 nucleotides from an isolated *spa* gene or a variant of least 12 nucleotides that hybridizes to an isolated *spa* gene under conditions of moderate or high stringency. Such sequences are useful for a variety of purposes including PCR primers for isolating additional *spa* sequences or variants thereof from other Streptococci. Another typical use is for recombinant expression of a peptide or polypeptide comprised of epitopes present on a native Spa polypeptide.

Also provided herein are nucleic acid fragments or oligonucleotides useful as probes and primers for identifying or obtaining Spa sequences. More specifically, a nucleic acid fragment or oligonucleotide that comprise at least 12 contiguous nucleotides of SEQ ID NO:1 or 4 are particularly useful for hybridization to  
5 Spa nucleic acid sequences and/or for primers that can be used to amplify the same. More particular embodiments include nucleic acid fragments or oligonucleotides where the length is at least 18, 24, 30, 50 or greater than 50 nucleotides. Complements of the above sequences are also included.

Another embodiment of nucleic acid fragments or oligonucleotides of  
10 this invention include those that encode a peptide epitope that can be detected, for example, by the ability to specifically bind to a Spa antibody or which can be used to elicit an immune response in an animal. Useful peptide epitopes are those capable of eliciting antibodies that specifically bind to the peptide or polypeptide comprised of the Spa amino acid residues, or that are capable of eliciting a T-cell response to the same.  
15 Peptide sequences of 8 or more amino acids are useful in this regard since it is generally understood by those skilled in the art that 8 amino acids is the lower size limit for a peptide to interact with the major histocompatibility complex (MHC). More preferred embodiments include nucleic acid fragments or oligonucleotides encoding at least 10, 15 or 20 amino acids.

20 Accordingly, the present invention provides nucleic acid fragments or oligonucleotides encoding a peptide comprised of at least 8 contiguous amino acids of the sequence according to SEQ ID NO:2, 5 or 5. Particular embodiments of this aspect include nucleic acid fragments or oligonucleotides encoding a peptide comprised of at least 10, 15, or 20 amino acids. Preferred embodiments include nucleic acid fragments  
25 wherein the encoded peptide comprises sequences from the N-terminus of a Spa polypeptide, and more particularly, sequences that encode opsonic epitopes. These include for example, sequences encoding peptides contained within SEQ ID NO: 2 or 3, or from an N-terminus of an internally located peptide isolated after cleavage of a larger Spa polypeptide such as for example, SEQ ID NO:5.

The invention also provides nucleic acids useful for modulating or inhibiting the expression of a Spa polypeptide in a cell. More specifically, the invention provides for ribozymes that cleaves RNA encoding the aforementioned Spa polypeptides and for antisense molecules that bind to such an RNA. This includes  
5 nucleic acid molecules comprising a sequence that encodes such a ribozyme or antisense molecule and vectors comprising the same. Particular embodiments include vectors wherein the aforementioned ribozyme or antisense nucleic acid is operably linked to a promoter. Typical embodiments of these vectors are selected from the group consisting of plasmid vectors, phage vectors, herpes simplex viral vectors, adenoviral  
10 vectors, adenovirus-associated viral vectors and retroviral vectors. Host cells comprising the above vectors are also included.

Ribozymes are provided which are capable of inhibiting expression of Spa RNA. As used herein, "ribozymes" are intended to include RNA molecules that contain anti-sense sequences for specific recognition, and an RNA-cleaving enzymatic  
15 activity. The catalytic strand cleaves a specific site in a target RNA at greater than stoichiometric concentration. A wide variety of ribozymes may be utilized within the context of the present invention, including for example, the hammerhead ribozyme (for example, as described by Forster and Symons, *Cell* 48:211-220, 1987; Haseloff and Gerlach, *Nature* 328:596-600, 1988; Walbot and Bruening, *Nature* 334:196, 1988;  
20 Haseloff and Gerlach, *Nature* 334:585, 1988); the hairpin ribozyme (for example, as described by Haseloff et al., U.S. Patent No. 5,254,678, issued October 19, 1993 and Hempel et al., European Patent Publication No. 0 360 257, published March 26, 1990); and *Tetrahymena* ribosomal RNA-based ribozymes (see Cech et al., U.S. Patent No. 4,987,071). Ribozymes of the present invention typically consist of RNA, but may also  
25 be composed of DNA, nucleic acid analogs (e.g., phosphorothioates), or chimerics thereof (e.g., DNA/RNA/RNA).

Antisense oligonucleotide molecules are provided which specifically inhibit expression of Spa nucleic acid sequences (see generally, Hirashima et al. in *Molecular Biology of RNA: New Perspectives* (M. Inouye and B. S. Dudock, eds., 1987  
30 Academic Press, San Diego, p. 401); *Oligonucleotides: Antisense Inhibitors of Gene*

*Expression* (J.S. Cohen, ed., 1989 MacMillan Press, London); Stein and Cheng, *Science* 261:1004-1012, 1993; WO 95/10607; U.S. Patent No. 5,359,051; WO 92/06693; and EP-A2-612844). Briefly, such molecules are constructed such that they are complementary to, and able to form Watson-Crick base pairs with, a region of transcribed *Spa* mRNA sequence. The resultant double-stranded nucleic acid interferes with subsequent processing of the mRNA, thereby preventing protein synthesis (Example 6).

Within a related aspect, any of the aforementioned nucleic acids may include modified nucleotides. Modified nucleotides can have modifications in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Analogous of phosphodiester linkages include phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like. The term "nucleic acid" also includes so-called "peptide nucleic acids," which comprise naturally-occurring or modified nucleic acid bases attached to a polyamide backbone. Nucleic acids can be either single stranded or double stranded.

It should be understood that *spa* genes include nucleic acid sequences encoding wild-type/native *Spa* polypeptides, as well as other variants (including alleles). Briefly, such variants may result from natural polymorphisms or be synthesized by recombinant methodology or chemical synthesis, and differ from wild-type polypeptides by one or more amino acid substitutions, insertions, deletions, or the like. Variants encompassing conservative amino acid substitutions include, for example, substitutions of one aliphatic amino acid for another, such as Ile, Val, Leu, or Ala or

substitutions of one polar residue for another, such as between Lys and Arg, Glu and Asp, or Gln and Asn. Such substitutions are well known in the art to provide variants having similar physical properties and functional activities such as for example, the ability to elicit and cross react with similar antibodies. Other variants include nucleic acids sequences that encode a polypeptide having at least 50%, 60%, 70%, 80%, 90% or 95% amino acid identity to SEQ ID NO:2, 3 or 5. Preferred embodiments are those having greater than 90% or 95% identity with the amino acid sequence of SEQ. ID NOS: 2 or 3 or 5. As will be appreciated by those of ordinary skill in the art, a nucleotide sequence encoding an Spa or a variant may differ from the native sequences presented herein due to codon degeneracies, nucleotide polymorphisms, or nucleotide substitutions, deletions or insertions.

While particular embodiments of such isolated nucleic acids are depicted in SEQ ID NOS:1 and 4 and Figures 4 and 5, within the context of the present invention, reference to one or more isolated nucleic acids includes variants of these sequences that are substantially similar in that they encode native or non native proteins, polypeptides or peptides with similar structure and function to the Spa polypeptide of SEQ. ID NOS: 2 or 5. As used herein, the nucleotide sequence is deemed to be "substantially similar" if: (a) the nucleotide sequence is derived from the coding region of a *spa* gene isolated from a Streptococcus (including, for example, portions of the sequence or allelic variations of the sequences discussed above) and contains a non-M protein epitope with substantially the same ability to elicit opsonic antibodies protective against Streptococci. or (b) the nucleotide sequence is capable of hybridization to the nucleotide sequences of the present invention under high stringency (e.g., capable of selectively hybridizing to nucleotide sequences a *spa* gene at least 42°C overnight in the presence of salts and/or formamide at least as stringent as 6X SSC and 50% formamide); or (c) the nucleotide sequences are degenerate (i.e., sequences which code for the same amino acids using a different codon sequences) as a result of the genetic code to the nucleotide sequences defined in (a) or (b); or (d) is a complement of any of the sequences described in (a), (b) or (c).

Another aspect of the present invention is the use of isolated *spa* nucleotide sequences to produce recombinant proteins for immunizing an animal. Therefore, the use of any length of nucleic acid disclosed by the present invention (preferably 24 nucleotides or longer) which encodes a polypeptide or fragment thereof  
5 of at least 8 contiguous amino acids which is capable of binding to the major histocompatibility complex and eliciting or enhancing an immunogenic response is contemplated by this invention. Preferred embodiments include polypeptides or fragments thereof that elicit opsonic antibodies. Immunogenic response can be readily tested by known methods such as challenging a mouse or rabbit with polypeptides or  
10 fragments of interest and thereafter collecting antisera and determining if the antibody of interest is present. Other assays particularly useful for the detection of T-cell responses include proliferation assays, T-cell cytotoxicity assays, assays for delayed hypersensitivity and assays for opsonization such as previously described. In determining whether an antibody specific for an antigen of interest is produced by the  
15 animal, many diagnostic tools are available, including for example, testing binding of antigen to antibodies contained in a sample antisera using conventional western blotting, or using enzyme-linked immunoassays with a tag attached to the antigen of interest.

The isolated nucleic acids encoding Spa polypeptides according to this  
20 invention can be obtained using a variety of methods. For example, a nucleic acid molecule can be obtained from a cDNA or genomic expression library by screening with an antibody or antibodies reactive with a Spa polypeptide (*see, e.g.,* Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, 1989; Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing, 1987). Further,  
25 random-primed PCR can be employed (*see, e.g., Methods in Enzymol.* 254:275, 1995). In addition, variations of random-primed PCR can also be used, especially when a particular gene or gene family is desired. In one such method, one of the primers is a random primer and the other is a degenerate primer based on the amino acid sequence or nucleotide sequence encoding a Spa polypeptide. This method is exemplified for  
30 example, in Example 7 where a codon degenerate primer designed to bind to a sequence

that encodes any one of several variants of a 23 amino acid N terminus of an isolated Spa polypeptide was used to isolate a 346 nucleotide sequence of a *spa* gene which is depicted in Figure 4 and SEQ. ID NO: 1.

Other methods can also be used to obtain isolated nucleic acid molecules  
5 that encode a Spa polypeptide. For example, a nucleic acid molecule can be isolated by using the sequence information provided herein to synthesize a probe which can be labeled, such as with a radioactive label, enzymatic label, protein label, fluorescent label, or the like, and hybridized to a genomic library or a cDNA library constructed in a phage, plasmid, phagemid, or viral vectors designed for replication or expression in  
10 selected host cells (*see, e.g.*, Sambrook et al. (*supra*); Ausubel et al. (*supra*)). DNA representing RNA or genomic nucleic acid sequence can also be obtained by amplification using sets of primers complementary to 5' and 3' sequences of the isolated nucleic acid sequences provided in SEQ. ID NO: 1 or to variants thereof as described above. For ease of cloning, restriction sites can also be incorporated into the  
15 primers.

Variants (including alleles) of the isolated *spa* nucleic acid sequence provided herein can be readily obtained from natural variants (*e.g.*, polymorphisms, mutants and other serotypes) either synthesized or constructed. Many methods have been developed for generating mutants (*see generally* Sambrook et al. (*supra*); Ausubel  
20 et al. (*supra*)). Briefly, preferred methods for generating nucleotide substitutions utilize an oligonucleotide that spans the base or bases to be mutated and contains the mutated base or bases. The oligonucleotide is hybridized to complementary single stranded nucleic acid and second strand synthesis is primed from the oligonucleotide. The double-stranded nucleic acid is prepared for transformation into host cells, such as *E.*  
25 *coli*, other prokaryotes, yeast or other eukaryotes. Standard screening and vector growth protocols are used to identify mutant sequences and obtain high yields.

Similarly, deletions and/or insertions of *spa* genes can be constructed by any of a variety of known methods. For example, the gene can be digested with restriction enzymes and/or nucleases and be religated such that sequences are deleted or  
30 religated with additional sequence such that an insertion or large substitution is made.



Similarly, a variety of transposons and other insertional elements may be used to make recombinants having deletions and insertions. Thus, in one example, a *spa* mutant containing a  $\Omega$  insertional element in a *spa* gene can be made in a manner similar to the making of the M18 $\Omega$  described above. Other means of generating variant sequences, known in the art, can be employed, for examples see Sambrook et al. (*supra*) and Ausubel et al. (*supra*). Moreover, verification of variant sequences is typically accomplished by restriction enzyme mapping, sequence analysis or hybridization. Variants which encode a polypeptide that elicits an immunogenic response specific to a Spa polypeptide are particularly useful in the context of this invention.

As noted above, the present invention provides isolated or purified Spa polypeptides proteins and peptides as those terms have been previously defined herein. In one aspect, these isolated or purified materials may be obtained from a host cell expressing a recombinant nucleic acid that encodes Spa polypeptides proteins or peptides which may be isolated from the host cell. The Spa polypeptides of the present invention can be purified by a variety of standard methods with or without a protease treatment or polyacrylamide electrophoresis step, and/or may be isolated from organisms other than Streptococci which have been engineered to express an isolated *spa* nucleic acid. For example, a Spa polypeptide of the present invention can be isolated by, among other methods, culturing suitable host and vector systems to produce a native Spa protein, polypeptide, fusion protein or peptide fusion using recombinant DNA methods (discussed further herein). Using these methods Spa may be engineered to be exported from the host cell, retained within the host cell, for example within inclusion bodies, or integrated into the surface of host cell as is the case for natural Spa expression in Streptococci. When engineered for export, a supernatant from a culture of the host cell can be used to isolate exported Spa polypeptides. When integrated into the surface, Spa polypeptides may be obtained by protease treatment to obtain a crude surface peptide fraction as previously described. When expressed in inclusion bodies, Spa proteins, fusion peptides and the like, can be obtained by a variety of purification procedures. For example, a Spa-containing extract can be applied to a suitable purification matrix such as a Spa antibody bound to a suitable support. Alternatively,

anion or cation exchange resins, gel filtration or affinity, hydrophobic or reverse phase chromatography may be employed in order to purify the protein. The Spa polypeptide can also be concentrated using commercially available protein concentration filters, such as an Amicon or Millipore Pellicon ultrafiltration unit, or by vacuum dialysis.

5 In one example of isolating Spa polypeptides, proteins or peptides by recombinant methods, an isolated nucleic acid encoding a Spa protein, polypeptide, or peptide can be expressed as a histidine-tagged molecule, permitting purification on a nickel-chelating matrix. Alternatively, other tags may be used, including FLAG and GST. The associated tag can then be removed in the last step of purification, for  
10 example, for certain vectors, His-tagged proteins may be incubated with thrombin, resulting in cleavage of a recognition sequence between the tag and the Spa polypeptide (*e.g.*, pET vectors from Invitrogen).

It is well known in the art that certain vectors (*e.g.*, pUC) can be used for producing multiple copies of a nucleotide molecule of interest as well as being useful  
15 for genetic manipulation techniques (*e.g.*, site-directed mutagenesis). See Sambrook (*supra*). Of particular interest to this disclosure are expression vectors. The expression vector includes transcriptional promoter/enhancer elements operably linked to an isolated nucleic acid molecule encoding a Spa polypeptide. The expression vector may be composed of either deoxyribonucleic acids ("DNA"), ribonucleic acids ("RNA"), or  
20 a combination of the two (*e.g.*, a DNA-RNA chimera). Optionally, the expression vector may include a polyadenylation sequence or one or more restriction sites. Additionally, depending on the host cell chosen and the expression vector employed, other genetic elements such as an origin of replication, additional nucleic acid restriction sites, enhancers, sequences conferring inducibility of transcription, and genes  
25 encoding proteins suitable for use as selectable or identifiable markers, may also be incorporated into the expression vectors described herein.

The manipulation and expression of *spa* genes can be accomplished by culturing host cells containing an expression vector capable of expressing the *spa* genes. Such vectors or vector constructs include either synthetic or cDNA-derived  
30 nucleic acid molecules or genomic DNA fragments encoding the Spa polypeptides,

which are operably linked to suitable transcriptional or translational regulatory elements. Suitable regulatory elements within the expression vector can be derived from a variety of sources, including bacterial, fungal, viral, mammalian, insect, or plant genes. Selection of appropriate regulatory elements is dependent on the host cell  
5 chosen, and can be readily accomplished by one of ordinary skill in the art in light of the present specification. Examples of regulatory elements include a transcriptional promoter and enhancer or RNA polymerase binding sequence, a transcriptional terminator, and a ribosomal binding sequence, including a translation initiation signal.

Nucleic acid molecules that encode any of the Spa protein, polypeptides,  
10 or peptides described above can be expressed by a wide variety of prokaryotic and eukaryotic host cells, including bacterial, mammalian, yeast or other fungi, viral, insect, and plant cells. The selection of a host cell may also assist the production of post-translationally modified Spa polypeptides, depending upon the desires of the user. Methods for transforming or transfecting such cells to express nucleic acids are well  
15 known in the art (*see, e.g.*, Itakura et al., U.S. Patent No. 4,704,362; Hinnen et al., *PNAS USA* 75:1929-1933, 1978; Murray et al., U.S. Patent No. 4,801,542; Upshall et al., U.S. Patent No. 4,935,349; Hagen et al., U.S. Patent No. 4,784,950; Axel et al., U.S. Patent No. 4,399,216; Goeddel et al., U.S. Patent No. 4,766,075; and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> edition, Cold Spring Harbor Laboratory  
20 Press, 1989; for plant cells see Czako and Marton, *Plant Physiol.* 104:1067-1071, 1994; Paszkowski et al., *Biotech.* 24:387-392, 1992).

Bacterial host cells suitable for carrying out the present invention include but are not limited to, numerous strains of *E. coli*, as well as various strains of *M. leprae*, *M. tuberculosis*, *M. bovis*, *B. subtilis*, *Salmonella typhimurium*, and various  
25 species within the genera *Pseudomonas*, *Streptomyces*, *Streptococcus*, and *Staphylococcus*, as well as many other bacterial species well known to one of ordinary skill in the art.

Bacterial expression vectors preferably comprise a promoter, which functions in the host cell, one or more selectable phenotypic markers, and a bacterial  
30 origin of replication. Representative promoters include the  $\beta$ -lactamase (penicillinase)

and lactose promoter system (see Chang et al., *Nature* 275:615, 1978), the T7 RNA polymerase promoter (Studier et al., *Meth. Enzymol.* 185:60-89, 1990), the lambda promoter (Elvin et al., *Gene* 87:123-126, 1990), the *trp* promoter (Nichols and Yanofsky, *Meth. in Enzymology* 101:155, 1983) and the *tac* promoter (Russell et al.,  
5 *Gene* 20:231, 1982). Representative selectable markers include various antibiotic resistance markers such as the kanamycin or ampicillin resistance genes. Many plasmids suitable for transforming host cells are well known in the art, including among others, pBR322 (see Bolivar et al., *Gene* 2:95, 1977), the pUC plasmids pUC18, pUC19, pUC118, pUC119 (see Messing, *Meth. in Enzymology* 101:20-77, 1983; Vieira  
10 and Messing, *Gene* 19:259-268, 1982), and pNH8A, pNH16a, pNH18a, and Bluescript M13 (Stratagene, La Jolla, Calif.). In one particular embodiment of this invention exemplified in Example 7, a 346 bp isolated nucleic acid encoding a Spa polypeptide was ligated into a pCR2.1-TOPO vector and expressed in *E. coli*.

Fungal host cells suitable for carrying out the present invention include,  
15 among others, *Saccharomyces pombe*, *Saccharomyces cerevisiae*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349). Suitable expression vectors for yeast and fungi include, among others, YCp50 (ATCC No. 37419) for yeast, and the *amdS* cloning vector pV3 (Turnbull, *Bio/Technology* 7:169, 1989), YRp7 (Struhl et al., *Proc. Natl. Acad. Sci.*  
20 *USA* 76:1035-1039, 1978), YEp13 (Broach et al., *Gene* 8:121-133, 1979), pJDB249 and pJDB219 (Beggs, *Nature* 275:104-108, 1978) and derivatives thereof.

Preferred promoters for use in yeast include promoters from yeast glycolytic genes (Hitzeman et al., *J. Biol. Chem.* 255:12073-12080, 1980; Alber and Kawasaki, *J. Mol. Appl. Genet.* 1:419-434, 1982) or alcohol dehydrogenase genes  
25 (Young et al., in *Genetic Engineering of Microorganisms for Chemicals*, Hollaender et al. (eds.), p. 355, Plenum, New York, 1982; Ammerer, *Meth. Enzymol.* 101:192-201, 1983). Examples of useful promoters for fungi vectors include those derived from *Aspergillus nidulans* glycolytic genes, such as the *adh3* promoter (McKnight et al., *EMBO J.* 4:2093-2099, 1985). The expression units may also include a transcriptional

terminator. An example of a suitable terminator is the *adh3* terminator (McKnight et al., *ibid.*, 1985).

As with bacterial vectors, the yeast vectors will generally include a selectable marker, which may be one of any number of genes that exhibit a dominant  
5 phenotype for which a phenotypic assay exists to enable transformants to be selected. Preferred selectable markers include those that complement host cell auxotrophy, provide antibiotic resistance or enable a cell to utilize specific carbon sources, and include *leu2* (Broach et al., *ibid.*), *ura3* (Botstein et al., *Gene* 8:17, 1979), or *his3* (Struhl et al., *ibid.*). Another suitable selectable marker is the *cat* gene, which confers  
10 chloramphenicol resistance on yeast cells.

Techniques for transforming fungi are well known in the literature, and have been described, for instance, by Beggs (*ibid.*), Hinnen et al. (*Proc. Natl. Acad. Sci. USA* 75:1929-1933, 1978), Yelton et al. (*Proc. Natl. Acad. Sci. USA* 81:1740-1747, 1984), and Russell (*Nature* 301:167-169, 1983). The genotype of the host cell may  
15 contain a genetic defect that is complemented by the selectable marker present on the expression vector. Choice of a particular host and selectable marker is well within the level of ordinary skill in the art in light of the present specification.

Protocols for the transformation of yeast are also well known to those of ordinary skill in the art. For example, transformation may be readily accomplished  
20 either by preparation of spheroplasts of yeast with DNA (*see* Hinnen et al., *PNAS USA* 75:1929, 1978) or by treatment with alkaline salts such as LiCl (*see* Itoh et al., *J. Bacteriology* 153:163, 1983). Transformation of fungi may also be carried out using polyethylene glycol as described by Cullen et al. (*Bio/Technology* 5:369, 1987).

Viral vectors include those that comprise a promoter that directs the  
25 expression of an isolated nucleic acid molecule that encodes a Spa polypeptide as described above. A wide variety of promoters may be utilized within the context of the present invention, including for example, promoters such as MoMLV LTR, RSV LTR, Friend MuLV LTR, adenoviral promoter (Ohno et al., *Science* 265: 781-784, 1994), neomycin phosphotransferase promoter/enhancer, late parvovirus promoter (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), Herpes TK promoter, SV40 promoter,  
30

metallothionein IIa gene enhancer/promoter, cytomegalovirus immediate early promoter, and the cytomegalovirus immediate late promoter. The promoter may also be a tissue-specific promoter (*see e.g.*, WO 91/02805; EP 0,415,731; and WO 90/07936). In addition to the above-noted promoters, other viral-specific promoters (*e.g.*, retroviral  
5 promoters (including those noted above, as well as others such as HIV promoters), hepatitis, herpes (*e.g.*, EBV), and bacterial, fungal or parasitic-specific (*e.g.*, malarial-specific) promoters may be utilized in order to target a specific cell or tissue which is infected with a virus, bacteria, fungus or parasite.

Thus, Spa polypeptides of the present invention may be expressed from a  
10 variety of viral vectors, including for example, herpes viral vectors (*e.g.*, U.S. Patent No. 5,288,641), adenoviral vectors (*e.g.*, WO 94/26914, WO 93/9191; Kolls et al., *PNAS* 91(1):215-219, 1994; Kass-Eisler et al., *PNAS* 90(24):11498-502, 1993; Guzman et al., *Circulation* 88(6):2838-48, 1993; Guzman et al., *Cir. Res.* 73(6):1202-1207, 1993; Zabner et al., *Cell* 75(2):207-216, 1993; Li et al., *Hum Gene Ther.* 4(4):403-409,  
15 1993; Caillaud et al., *Eur. J. Neurosci.* 5(10):1287-1291, 1993; Vincent et al., *Nat. Genet.* 5(2):130-134, 1993; Jaffe et al., *Nat. Genet.* 1(5):372-378, 1992; and Levrero et al., *Gene* 101(2):195-202, 1991), adenovirus-associated viral vectors (Flotte et al., *PNAS* 90(22):10613-10617, 1993), baculovirus vectors, parvovirus vectors (Koering et al., *Hum. Gene Therap.* 5:457-463, 1994), pox virus vectors (Panicali and Paoletti,  
20 *PNAS* 79:4927-4931, 1982; and Ozaki et al., *Biochem. Biophys. Res. Comm.* 193(2):653-660, 1993), and retroviruses (*e.g.*, EP 0,415,731; WO 90/07936; WO 91/0285, WO 94/03622; WO 93/25698; WO 93/25234; U.S. Patent No. 5,219,740; WO 93/11230; WO 93/10218. Within various embodiments, either the viral vector itself or a viral particle which contains the viral vector may be utilized in the methods and  
25 compositions described below.

Mammalian cells suitable for carrying out the present invention include, among others: PC12 (ATCC No. CRL1721), N1E-115 neuroblastoma, SK-N-BE(2)C neuroblastoma, SHSY5 adrenergic neuroblastoma, NS20Y and NG108-15 murine cholinergic cell lines, or rat F2 dorsal root ganglion line, COS (*e.g.*, ATCC No. CRL  
30 1650 or 1651), BHK (*e.g.*, ATCC No. CRL 6281; BHK 570 cell line (deposited with

the American Type Culture Collection under accession number CRL 10314), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573; Graham et al., *J. Gen. Virol.* 36:59-72, 1977) and NS-1 cells. Other mammalian cell lines may be used within the present invention, including Rat Hep I (ATCC No. CRL 1600), Rat  
5 Hep II (ATCC No. CRL 1548), TCMK (ATCC No. CCL 139), Human lung (ATCC No. CCL 75.1), Human hepatoma (ATCC No. HTB-52), Hep G2 (ATCC No. HB 8065), Mouse liver (ATCC No. CCL 29.1), NCTC 1469 (ATCC No. CCL 9.1), SP2/0-Ag14 (ATCC No. 1581), HIT-T15 (ATCC No. CRL 1777), and RINm 5AHT2B (Orskov and Nielson, *FEBS* 229(1):175-178, 1988).

10 Mammalian expression vectors for use in carrying out the present invention include a promoter capable of directing the transcription of a cloned gene or cDNA. Preferred promoters include viral promoters and cellular promoters. Viral promoters include the cytomegalovirus immediate early promoter (Boshart et al., *Cell* 41:521-530, 1985), cytomegalovirus immediate late promoter, SV40 promoter  
15 (Subramani et al., *Mol. Cell. Biol.* 1:854-864, 1981), MMTV LTR, RSV LTR, metallothionein-1, adenovirus E1a. Cellular promoters include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), action promoters, a mouse V<sub>H</sub> promoter (Bergman et al., *Proc. Natl. Acad. Sci. USA* 81:7041-7045, 1983; Grant et al., *Nucl. Acids Res.* 15:5496, 1987) and a mouse V<sub>H</sub> promoter  
20 (Loh et al., *Cell* 33:85-93, 1983). The choice of promoter will depend, at least in part, upon the level of expression desired or the recipient cell line to be transfected.

Such expression vectors can also contain a set of RNA splice sites located downstream from the promoter and upstream from the DNA sequence encoding the peptide or protein of interest. Preferred RNA splice sites may be obtained from  
25 adenovirus and/or immunoglobulin genes. Also contained in the expression vectors is a polyadenylation signal located downstream of the coding sequence of interest. Suitable polyadenylation signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *ibid.*), the polyadenylation signal from the Adenovirus 5 E1B region and the human growth hormone gene terminator (DeNoto et al., *Nuc. Acids Res.*  
30 9:3719-3730, 1981). The expression vectors may include a noncoding viral leader

sequence, such as the Adenovirus 2 tripartite leader, located between the promoter and the RNA splice sites. Preferred vectors may also include enhancer sequences, such as the SV40 enhancer. Expression vectors may also include sequences encoding the adenovirus VA RNAs. Suitable expression vectors can be obtained from commercial  
5 sources (*e.g.*, Stratagene, La Jolla, Calif.).

Vector constructs comprising isolated *spa* sequences can be introduced into cultured mammalian cells by, for example, calcium phosphate-mediated transfection (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), electroporation  
10 (Neumann et al., *EMBO J.* 1:841-845, 1982), or DEAE-dextran mediated transfection (Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc., NY, 1987). *See generally* Sambrook et al. (*supra*). To identify cells that have stably integrated the cloned DNA, a selectable marker is generally introduced into the  
15 cultured mammalian cells include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. The selectable marker may be an amplifiable selectable marker. Preferred amplifiable selectable markers are the DHFR gene and the neomycin resistance gene. Selectable markers are reviewed by Thilly (*Mammalian Cell Technology*, Butterworth Publishers, Stoneham, MA).

20 Mammalian cells containing a suitable vector are allowed to grow for a period of time, typically 1-2 days, to begin expressing the DNA sequence(s) of interest. Drug selection is then applied to select for growth of cells that are expressing the selectable marker in a stable fashion. For cells that have been transfected with an amplifiable, selectable marker the drug concentration may be increased in a stepwise  
25 manner to select for increased copy number of the cloned sequences, thereby increasing expression levels. Cells expressing the introduced sequences are selected and screened for production of the protein of interest in the desired form or at the desired level. Cells that satisfy these criteria can then be cloned and scaled up for production.

Numerous insect host cells known in the art can also be useful within the  
30 present invention, in light of the subject specification. For example, the use of



baculoviruses as vectors for expressing heterologous DNA sequences in insect cells has been reviewed by Atkinson et al. (*Pestic. Sci.* 28:215-224,1990).

Numerous plant host cells known in the art can also be useful within the present invention, in light of the subject specification. For example, the use of  
5 *Agrobacterium rhizogenes* as vectors for expressing genes in plant cells has been reviewed by Sinkar et al., *J. Biosci. (Bangalore)* 11:47-58, 1987.

Upon expression of the Spa polypeptides or fragments thereof in the host cells, the polypeptide or peptide may be preliminarily released and/or isolated from the host cell utilizing methods such as those discussed previously herein.

10 As noted above, depending on the host cell in which one desires to express a Spa polypeptide, an isolated nucleic acid encoding the polypeptide is introduced into an expression vector comprising a promoter that is active in the host cell. Other components of the expression unit such as transcribed but not translated sequences at the ends of the coding region may also be selected according to the  
15 particular host utilized. In some cases, it may be necessary to introduce artificially an intervening sequence to ensure high level expression. Expression can be monitored by SDS-PAGE and staining, if expression levels are sufficiently high. Additionally, if the protein is produced with a tag, detection by anti-tag antibody can be carried out and if produced with no tag, detection by anti-Spa antibody that does not recognize  
20 homologous proteins of the host may be employed. Further, any method known in the art for protein identification may be utilized to this end (e.g., a high resolution electrophoretic method or 2D electrophoresis).

### III. Antibodies

In another aspect, the proteins of the present invention are utilized to  
25 prepare antibodies that specifically bind to an epitope present on Spa polypeptides. Accordingly, the present invention also provides such antibodies. In preferred embodiments the antibodies bind to specific opsonic epitopes present on a Spa polypeptide. In a typical embodiment, the antibodies do not bind to epitopes present on M-proteins of a *Streptococcus* species. Within the context of the present invention, the

term "antibodies" includes polyclonal antibodies, monoclonal antibodies, anti-idiotypic antibodies, fragments thereof such as  $F(ab')_2$  and Fab fragments, and recombinantly or synthetically produced antibodies. Such antibodies incorporate the variable regions that permit a monoclonal antibody to specifically bind, which means an antibody able to  
5 selectively bind to a peptide produced from a *spa* gene of this invention. The affinity of a monoclonal antibody or antibody can be readily determined by one of ordinary skill in the art (see Scatchard, *Ann. N.Y. Acad. Sci.* 51:660-672, 1949).

Polyclonal antibodies can be readily generated by one of ordinary skill in the art from a variety of warm-blooded animals such as horses, cows, goats, sheep,  
10 dogs, chickens, turkeys, rabbits, mice, or rats. Briefly, the desired protein or peptide is utilized to immunize the animal through intraperitoneal, intramuscular, intraocular, or subcutaneous injections. The immunogenicity of the protein or peptide of interest may be increased through the use of an adjuvant such as Freund's complete or incomplete adjuvant. Following several booster immunizations, small samples of serum are  
15 collected and tested for reactivity to the desired protein or peptide.

Particularly preferred polyclonal antisera give a signal that is at least three times greater than background. Once the titer of the animal has reached a plateau in terms of its reactivity to the protein, larger quantities of polyclonal antisera may be readily obtained either by weekly bleedings, or by exsanguinating the animal.

20 Monoclonal antibodies can also be readily generated using well-known techniques (see U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439, and 4,411,993; see also *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), 1980, and *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press,  
25 1988). Briefly, in one embodiment, a subject animal such as a rat or mouse is injected with a desired protein or peptide. If desired, various techniques may be utilized in order to increase the resultant immune response generated by the protein, in order to develop greater antibody reactivity. For example, the desired protein or peptide may be coupled to another carrier protein such as ovalbumin or keyhole limpet hemocyanin (KLH), or  
30 through the use of adjuvants such as Freund's complete or incomplete adjuvant.

The present invention also provides fusion polypeptides or proteins containing a portion of a Spa polypeptide. Fusion proteins are useful for several purposes, including the combining of two or more catalytic functions from separate polypeptide sources, and for raising antibodies to epitopes. For raising antibodies to  
5 epitopes, the fusion protein typically contains a peptide epitope of a Spa of at least 8, 10, 15 or 20 amino acids fused to a protein that enhances an immune response to the epitope. A typical protein for this purpose is KLH. Therefore, another aspect of the present invention provides a non-naturally occurring fusion protein, comprising a first Spa polypeptide segment comprised of at least 8 contiguous amino acids of a Spa  
10 polypeptide or variant described above, fused in-frame to a second polypeptide segment. More preferred embodiments include Spa polypeptide segments of at least 10, 15 or 20 amino acids. The second polypeptide segment may optionally comprise another portion of the Spa polypeptide that is not naturally adjacent to the first segment, or comprise sequences from a non-Spa polypeptide. Also provided are nucleic acids  
15 and vectors encoding the aforementioned fusion proteins and host cells carrying the same.

Use of carrier proteins, fusion proteins or linkers is particularly advantageous when antibody is to be raised against a peptide antigen carrying an opsonic epitope. One example of coupling to a carrier protein is shown in Example 5  
20 where a synthetic 23 amino acid peptide comprising an N-terminus of a Spa polypeptides was linked to KLH in order to produce antibodies against an opsonic epitope contained within the peptide. Other suitable carrier proteins include but are not limited to tetanus toxoid, diphtheria toxoid, bovine serum albumin, hen egg lysozyme, gelatin, bovine gamma globulin, B subunit of cholera toxin, B subunit of *E. coli* labile  
25 toxin, and flagellin polymer. Typically, linking a Spa epitope to a carrier protein will usually include an in frame fusion of the peptide through a linker amino acid sequence of at least 2 amino acids in length. More typically the linker is 7 to 35 amino acids, and most typically about 7 to 15 amino acids wherein 2 to 7 of the linker amino acids are hydrophobic amino acids. The initial elicitation of an immune response may preferably  
30 be through intraperitoneal, intramuscular, intranasal, oral, or subcutaneous routes.

Between one and three weeks after the initial immunization, the animal may be reimmunized. The animal may then be test bled and the serum tested for binding to the desired antigen using assays as described above. Additional immunizations may also be accomplished until the animal has reached a plateau in its reactivity to the desired protein or peptide. The animal may then be given a final boost of the desired protein or peptide, and three to four days later sacrificed. At this time, the spleen and lymph nodes may be harvested and disrupted into a single cell suspension by passing the organs through a mesh screen or by rupturing the spleen or lymph node membranes which encapsulate the cells. Within one embodiment the red cells are subsequently lysed by the addition of a hypotonic solution, followed by immediate return to isotonicity.

Within another embodiment, suitable cells for preparing monoclonal antibodies are obtained through the use of *in vitro* immunization techniques. Briefly, an animal is sacrificed, and the spleen and lymph node cells are removed as described above. A single cell suspension is prepared, and the cells are placed into a culture containing a form of the protein or peptide of interest that is suitable for generating an immune response as described above. Subsequently, the lymphocytes are harvested and fused as described below.

Cells that are obtained through the use of *in vitro* immunization or from an immunized animal as described above may be immortalized by transfection with a virus such as the Epstein-Barr Virus (EBV). (See Glasky and Reading, *Hybridoma* 8(4):377-389, 1989.) Alternatively, within a preferred embodiment, the harvested spleen and/or lymph node cell suspensions are fused with a suitable myeloma cell in order to create a "hybridoma" which secretes monoclonal antibodies. Suitable myeloma lines are preferably defective in the construction or expression of antibodies, and are additionally syngeneic with the cells from the immunized animal. Many such myeloma cell lines are well known in the art and may be obtained from sources such as the American Type Culture Collection (ATCC), Rockville, Maryland (see *Catalogue of Cell Lines & Hybridomas*, 6<sup>th</sup> ed., ATCC, 1988). Representative myeloma lines include: for humans, UC 729-6 (ATCC No. CRL 8061), MC/CAR-Z2 (ATCC

No. CRL 8147), and SKO-007 (ATCC No. CRL 8033); for mice, SP2/0-Ag14 (ATCC No. CRL 1581), and P3X63Ag8 (ATCC No. TIB 9); and for rats, Y3-Ag1.2.3 (ATCC No. CRL 1631), and YB2/0 (ATCC No. CRL 1662). Particularly preferred fusion lines include NS-1 (ATCC No. TIB 18) and P3X63 -Ag 8.653 (ATCC No. CRL 1580),  
5 which may be utilized for fusions with either mouse, rat, or human cell lines. Fusion between the myeloma cell line and the cells from the immunized animal can be accomplished by a variety of methods, including the use of polyethylene glycol (PEG) (*see Antibodies: A Laboratory Manual*, Harlow and Lane, *supra*) or electrofusion. (*See* Zimmerman and Vienken, *J. Membrane Biol.* 67:165-182, 1982.)

10               Following the fusion, the cells are placed into culture plates containing a suitable medium, such as RPMI 1640 or DMEM (Dulbecco's Modified Eagles Medium, JRH Biosciences, Lenexa, Kan.). The medium may also contain additional ingredients, such as Fetal Bovine Serum (FBS, *e.g.*, from Hyclone, Logan, Utah, or JRH Biosciences), thymocytes that were harvested from a baby animal of the same  
15 species as was used for immunization, or agar to solidify the medium. Additionally, the medium should contain a reagent which selectively allows for the growth of fused spleen and myeloma cells. Particularly preferred is the use of HAT medium (hypoxanthine, aminopterin, and thymidine) (Sigma Chemical Co., St. Louis, Mo.). After about seven days, the resulting fused cells or hybridomas may be screened in  
20 order to determine the presence of antibodies which recognize the desired antigen. Following several clonal dilutions and reassays, hybridoma producing antibodies that bind to the protein of interest can be isolated.

Other techniques may also be utilized to construct monoclonal antibodies. (*See* Huse et al., "Generation of a Large Combinational Library of the  
25 Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281, 1989; *see also* Sastry et al., "Cloning of the Immunological Repertoire in *Escherichia coli* for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," *Proc. Natl. Acad. Sci. USA* 86:5728-5732, 1989; *see also* Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A  
30 Rapid Alternative to Hybridomas," *Strategies in Molecular Biology* 3:1-9, 1990; these

references describe a commercial system available from Stratagene, La Jolla, California, which enables the production of antibodies through recombinant techniques.) Briefly, mRNA is isolated from a B cell population and utilized to create heavy and light chain immunoglobulin cDNA expression libraries in the  $\lambda$  IMMUNOZAP(H) and  $\lambda$ IMMUNOZAP(L) vectors. These vectors may be screened individually or co-expressed to form Fab fragments or antibodies (*see* Huse et al. (*supra*); *see also* Sastry et al. (*supra*)). Positive plaques can subsequently be converted to a non-lytic plasmid which allows high level expression of monoclonal antibody fragments from *E. coli*.

Similarly, antibodies can also be constructed utilizing recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specifically binding antibody. The construction of these antibodies can be readily accomplished by one of ordinary skill in the art given the disclosure provided herein. (*See* Larrick et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells," *Biotechnology* 7:934-938, 1989; Riechmann et al., "Reshaping Human Antibodies for Therapy," *Nature* 332:323-327, 1988; Roberts et al., "Generation of an Antibody with Enhanced Affinity and Specificity for its Antigen by Protein Engineering," *Nature* 328:731-734, 1987; Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," *Science* 239:1534-1536, 1988; Chaudhary et al., "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to *Pseudomonas* Exotoxin," *Nature* 339:394-397, 1989; *see also* U.S. Patent No. 5,132,405 entitled "Biosynthetic Antibody Binding Sites.") Briefly, in one embodiment, DNA segments encoding the desired protein or peptide of interest-specific antigen binding domains are amplified from hybridomas that produce a specifically binding monoclonal antibody, and are inserted directly into the genome of a cell that produces human antibodies. (*See* Verhoeyen et al. (*supra*); *see also* Reichmann et al. (*supra*)). This technique allows the antigen-binding site of a specifically binding mouse or rat monoclonal antibody to be transferred into a human antibody. Such antibodies are preferable for therapeutic use in humans because they are not as antigenic as rat or mouse antibodies.

In an alternative embodiment, genes that encode the variable region from a hybridoma producing a monoclonal antibody of interest are amplified using oligonucleotide primers for the variable region. These primers may be synthesized by one of ordinary skill in the art, or may be purchased from commercially available sources. For instance, primers for mouse and human variable regions including, among others, primers for V<sub>Ha</sub>, V<sub>Hb</sub>, V<sub>Hc</sub>, V<sub>Hd</sub>, C<sub>H1</sub>, V<sub>L</sub> and C<sub>L</sub> regions, are available from Stratagene (La Jolla, Calif.). These primers may be utilized to amplify heavy or light chain variable regions, which may then be inserted into vectors such as IMMUNOZAP™(H) or IMMUNOZAP™(L) (Stratagene), respectively. These vectors may then be introduced into *E. coli* for expression. Utilizing these techniques, large amounts of a single-chain polypeptide containing a fusion of the V<sub>H</sub> and V<sub>L</sub> domains may be produced (see Bird et al., *Science* 242:423-426, 1988).

Monoclonal antibodies and other antibodies can be produced in a number of host systems, including tissue cultures, bacteria, eukaryotic cells, plants and other host systems known in the art.

Once suitable antibodies or antibodies have been obtained, they may be isolated or purified by many techniques well known to those of ordinary skill in the art (see *Antibodies: A Laboratory Manual*, Harlow and Lane (*supra*)). Suitable techniques include peptide or protein affinity columns, HPLC or RP-HPLC, purification on protein A or protein G columns, or any combination of these techniques. Within the context of the present invention, the term "isolated" as used to define antibodies or antibodies means "substantially free of other blood components."

The antibodies of the present invention have many uses. For example, antibodies can be utilized in flow cytometry to identify cells bearing such a protein. Briefly, in order to detect the protein or peptide of interest on cells, the cells are incubated with a labeled monoclonal antibody which specifically binds to the protein of interest, followed by detection of the presence of bound antibody. Labels suitable for use within the present invention are well known in the art including, among others, fluorescein isothiocyanate (FITC), phycoerythrin (PE), horse radish peroxidase (HRP), and colloidal gold. Particularly preferred for use in flow cytometry is FITC, which may

be conjugated to purified antibody according to the method of Keltkamp in "Conjugation of Fluorescein Isothiocyanate to Antibodies. I. Experiments on the Conditions of Conjugation," *Immunology* 18:865-873, 1970. (See also Keltkamp, "Conjugation of Fluorescein Isothiocyanate to Antibodies. II. A Reproducible Method," *Immunology* 18:875-881, 1970; Goding, "Conjugation of Antibodies with Fluorochromes: Modification to the Standard Methods," *J. Immunol. Methods* 13:215-226, 1970.) The antibodies can also be used to target drugs against Streptococci, to diagnose infection by these bacteria, or for treating an infection caused thereby.

#### IV. Diagnostic Application of Spa Nucleotide Sequences

10 Nucleic acid molecules can be used to detect the expression of the *spa* gene in a biological sample. Such probe molecules include double-stranded nucleic acid molecules comprising the nucleotide sequence of SEQ ID NOS:1 or 4 or a fragment thereof, as well as single-stranded nucleic acid molecules having the complement of the nucleotide sequence of SEQ ID NOS:1 or 4 or a fragment thereof.

15 Probe molecules may be DNA, RNA, oligonucleotides, and the like.

Preferred probes bind with regions of the *spa* gene that have a low sequence similarity to comparable regions in other Streptococcal proteins. For example, suitable probes will bind with at least one portion of the nucleotide sequence of SEQ ID NO:1. As used herein, the term "portion" refers to at least eight or more

20 nucleotides.

In a basic assay, a single-stranded probe molecule is incubated with RNA, isolated from a biological sample, under conditions of temperature and ionic strength that promote base pairing between the probe and target *Spa* RNA species. After separating unbound probe from hybridized molecules, the amount of hybrids is

25 detected.

Well-established hybridization methods of RNA detection include northern analysis and dot/slot blot hybridization (see, for example, Ausubel (1995) at pages 4-1 to 4-27, and Wu et al. (eds.), "Analysis of Gene Expression at the RNA Level," in *Methods in Gene Biotechnology*, pages 225-239 (CRC Press, Inc. 1997)).



Nucleic acid probes can be detectably labeled with radioisotopes such as  $^{32}\text{P}$  or  $^{35}\text{S}$ . Alternatively, *Spa* RNA can be detected with a nonradioactive hybridization method (see, for example, Isaac (ed.), *Protocols for Nucleic Acid Analysis by Nonradioactive Probes* (Humana Press, Inc. 1993)). Typically, nonradioactive detection is achieved by enzymatic  
5 conversion of chromogenic or chemiluminescent substrates. Illustrative nonradioactive moieties include biotin, fluorescein, and digoxigenin.

Numerous diagnostic procedures take advantage of the polymerase chain reaction (PCR) to increase sensitivity of detection methods. Standard techniques for performing PCR are well-known (see, generally, Mathew (ed.), *Protocols in Human*  
10 *Molecular Genetics* (Humana Press, Inc. 1991), White (ed.), *PCR Protocols: Current Methods and Applications* (Humana Press, Inc. 1993), Cotter (ed.), *Molecular Diagnosis of Cancer* (Humana Press, Inc. 1996), Hanausek and Walaszek (eds.), *Tumor Marker Protocols* (Humana Press, Inc. 1998), Lo (ed.), *Clinical Applications of PCR* (Humana Press, Inc. 1998), and Meltzer (ed.), *PCR in Bioanalysis* (Humana Press, Inc.  
15 1998)).

Preferably, PCR primers are designed to amplify a portion of the *spa* gene that has a low sequence similarity to other Streptococcal proteins. As an illustration, primers having the nucleotide sequences of SEQ. ID NOS: 6 and 7 are suitable for amplifying a *spa* gene from several Streptococci. In addition suitable  
20 primers include those designed to amplify portions of a *spa* gene encoding an immunogenic epitope of SEQ ID NOS: 2 or 5.

One variation of PCR for diagnostic assays is reverse transcriptase-PCR (RT-PCR). RT-PCR has been used to detect dissemination of prostate cancer cells to metastatic sites in prostate cancer patients (Moreno et al., *Cancer Res.* 52:6110, 1992;  
25 Vessella et al., *Proc. Am. Assoc. Can. Res.* 33:2367, 1992; Olsson et al., *Urologic Clinics of North America* 24:367 (1997); Robbins, International Publication No. WO 97/39139). In the RT-PCR technique, RNA is isolated from a biological sample, reverse transcribed to cDNA, and the cDNA is incubated with *Spa* primers (see, for example, Wu et al. (eds.), "Rapid Isolation of Specific cDNAs or Genes by PCR," in

*Methods in Gene Biotechnology*, pages 15-28 (CRC Press, Inc. 1997)). PCR is then performed and the products are analyzed using standard techniques.

Briefly, a biological sample is obtained from a sample for RNA preparation. If the test material contains a variety of biological materials, then the sample may be layered onto a Ficoll-Hypaque density gradient and centrifuged in order to separate some of the biological materials.

RNA may then be isolated from the sample using, for example, the guanadinium-thiocyanate cell lysis procedure described above. Alternatively, a solid-phase technique can be used to isolate mRNA from a cell lysate. A reverse transcription reaction can be primed with the isolated RNA using random oligonucleotides, short homopolymers of dT, or *Spa* antisense oligomers. Oligo-dT primers offer the advantage that various mRNA nucleotide sequences are amplified that can provide control target sequences. *Spa* sequences are amplified by the polymerase chain reaction using two flanking oligonucleotide primers that are typically 20 bases in length.

PCR amplification products can be detected using a variety of approaches. For example, PCR products can be fractionated by gel electrophoresis, and visualized by ethidium bromide staining. Alternatively, fractionated PCR products can be transferred to a membrane, hybridized with a detectably-labeled *Spa* probe, and examined by autoradiography. Additional alternative approaches include the use of digoxigenin-labeled deoxyribonucleic acid triphosphates to provide chemiluminescence detection, and the C-TRAK colorimetric assay.

Another approach for detection of *Spa* expression is cycling probe technology (CPT), in which a single-stranded DNA target binds with an excess of DNA-RNA-DNA chimeric probe to form a complex, the RNA portion is cleaved with RNAase H, and the presence of cleaved chimeric probe is detected (see, for example, Beggs et al., *J. Clin. Microbiol.* 34:2985, 1996, Bekkaoui et al., *Biotechniques* 20:240, 1996). Alternative methods for detection of *Spa* sequences can utilize approaches such as nucleic acid sequence-based amplification (NASBA), cooperative amplification of templates by cross-hybridization (CATCH), and the ligase chain reaction (LCR) (see,

for example, Marshall et al., U.S. Patent No. 5,686,272 (1997), Dyer et al., *J. Virol. Methods* 60:161, 1996, Ehricht et al., *Eur. J. Biochem.* 243:358, 1997, and Chadwick et al., *J. Virol. Methods* 70:59, 1998). Other standard methods are known to those of skill in the art.

5                Various additional diagnostic approaches are well-known to those of skill in the art (see, for example, Mathew (ed.), *Protocols in Human Molecular Genetics* (Humana Press, Inc. 1991), Coleman and Tsongalis, *Molecular Diagnostics* (Humana Press, Inc. 1996), and Elles, *Molecular Diagnosis of Genetic Diseases* (Humana Press, Inc., 1996)).

10              The present invention also contemplates kits for performing a diagnostic assay for *spa* gene expression. Such kits comprise nucleic acid probes comprising a portion of the nucleotide sequence of SEQ ID NOS:1 or 4, or a fragment thereof, or nucleic acids encoding a peptide according to SEQ. ID NOS: 2, 3 or 5 or fragments thereof. Probe molecules may be DNA, RNA, oligonucleotides, and the like. Kits may  
15              comprise nucleic acid primers for performing PCR.

                Preferably, such a kit contains all the necessary elements to perform a nucleic acid diagnostic assay described above. A kit will comprise one or more containers, in which one container comprises a *Spa* probe or primer, and a second container comprises one or more reagents capable of indicating the presence of *Spa*  
20              sequences. Examples of such indicator reagents include detectable labels such as radioactive labels, fluorochromes, chemiluminescent agents, and the like. A kit will also comprise written material describing the use of such *Spa* probes and primers for detection of *spa* gene expression. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.

#### 25              V. Diagnostic Application of Anti-Spa Antibodies

                The present invention further contemplates the use of anti-Spa antibodies to screen biological samples *in vitro* for the presence of Spa. In one type of *in vitro* assay, anti-Spa antibodies are used in liquid phase. For example, the presence of Spa in a biological sample can be tested by mixing the biological sample with a trace amount of

labeled Spa and an anti-Spa antibody under conditions that promote binding between Spa and its antibody. Complexes of Spa and anti-Spa in the sample can be separated from the reaction mixture by contacting the complex with an immobilized protein which binds with the antibody, such as an Fc antibody or *Staphylococcus* protein A. The  
5 concentration of Spa in the biological sample will be inversely proportional to the amount of labeled Spa bound to the antibody and directly related to the amount of free labeled Spa.

Alternatively, *in vitro* assays can be performed in which anti-Spa antibody is bound to a solid-phase carrier. For example, antibody can be attached to a  
10 polymer, such as aminodextran, in order to link the antibody to an insoluble support such as a polymer-coated bead, a plate or a tube. Other suitable *in vitro* assays will be readily apparent to those of skill in the art.

Immunochemical detection can be performed by contacting a biological sample with an anti-Spa antibody, and then contacting the biological sample with a  
15 detectably labeled molecule which binds to the antibody. For example, the detectably labeled molecule can comprise an antibody moiety that binds to anti-Spa antibody. Alternatively, the anti-Spa antibody can be conjugated with avidin/streptavidin (or biotin) and the detectably labeled molecule can comprise biotin (or avidin/streptavidin). Numerous variations of this basic technique are well-known to those of skill in the art.

20 Alternatively, an anti-Spa antibody can be conjugated with a detectable label to form an anti-Spa immunoconjugate. Suitable detectable labels include, for example, a radioisotope, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label or colloidal gold. Methods of making and detecting such detectably-labeled immunoconjugates are well-known to those of ordinary skill in the  
25 art, and are described in more detail below.

The detectable label can be a radioisotope that is detected by autoradiography. Isotopes that are particularly useful for the purpose of the present invention are  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{35}\text{S}$  and  $^{14}\text{C}$ .

Anti-Spa immunoconjugates can also be labeled with a fluorescent  
30 compound. The presence of a fluorescently-labeled antibody is determined by exposing

the immunoconjugate to light of the proper wavelength and detecting the resultant fluorescence. Fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, *o*-phthaldehyde and fluorescamine.

5                   Alternatively, anti-Spa immunoconjugates can be detectably labeled by coupling an antibody component to a chemiluminescent compound. The presence of the chemiluminescent-tagged immunoconjugate is determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of chemiluminescent labeling compounds include luminol, isoluminol, an aromatic  
10   acridinium ester, an imidazole, an acridinium salt and an oxalate ester.

                  Similarly, a bioluminescent compound can be used to label anti-Spa immunoconjugates of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent  
15   protein is determined by detecting the presence of luminescence. Bioluminescent compounds that are useful for labeling include luciferin, luciferase and aequorin.

                  Alternatively, anti-Spa immunoconjugates can be detectably labeled by linking an anti-Spa antibody component to an enzyme. When the anti-Spa-enzyme conjugate is incubated in the presence of the appropriate substrate, the enzyme moiety  
20   reacts with the substrate to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means. Examples of enzymes that can be used to detectably label polyspecific immunoconjugates include  $\beta$ -galactosidase, glucose oxidase, peroxidase and alkaline phosphatase.

                  Those of skill in the art will know of other suitable labels which can be  
25   employed in accordance with the present invention. The binding of marker moieties to anti-Spa antibodies can be accomplished using standard techniques known to the art. Typical methodology in this regard is described by Kennedy et al., *Clin. Chim. Acta* 70:1, 1976, Schurs et al., *Clin. Chim. Acta* 81:1, 1977, Shih et al., *Int'l J. Cancer* 46:1101, 1990, Stein et al., *Cancer Res.* 50:1330, 1990), and Coligan, *supra*.

Moreover, the convenience and versatility of immunochemical detection can be enhanced by using anti-Spa antibodies that have been conjugated with avidin, streptavidin, and biotin (see, for example, Wilchek et al. (eds.), "Avidin-Biotin Technology," *Methods In Enzymology*, Vol. 184 (Academic Press 1990), and Bayer et al., "Immunochemical Applications of Avidin-Biotin Technology," in *Methods In Molecular Biology*, Vol. 10, Manson (ed.), pages 149-162 (The Humana Press, Inc. 1992).

Methods for performing immunoassays are well-established (see, for example, Cook and Self, "Monoclonal Antibodies in Diagnostic Immunoassays," in *Monoclonal Antibodies: Production, Engineering, and Clinical Application*, Ritter and Ladyman (eds.), pages 180-208, (Cambridge University Press, 1995), Perry, "The Role of Monoclonal Antibodies in the Advancement of Immunoassay Technology," in *Monoclonal Antibodies: Principles and Applications*, Birch and Lennox (eds.), pages 107-120 (Wiley-Liss, Inc. 1995), and Diamandis, *Immunoassay* (Academic Press, Inc. 1996)).

The present invention also contemplates kits for performing an immunological diagnostic assay for *spa* genes. Such kits comprise one or more containers, in which one container comprises an anti-Spa antibody, or antibody fragment. A second container may comprise one or more reagents capable of indicating the presence of Spa antibody or antibody fragments. Examples of such indicator reagents include detectable labels such as a radioactive label, a fluorescent label, a chemiluminescent label, an enzyme label, a bioluminescent label, colloidal gold, and the like. A kit will also comprise written material describing the use of Spa antibodies and antibody fragments for detection of Spa protein. The written material can be applied directly to a container, or the written material can be provided in the form of a packaging insert.

#### VI. Therapeutic compositions.

The discovery of a new protective antigen of group A Streptococci enables another aspect of this invention which is the provision of therapeutic

compositions to protect against infections caused by group A Streptococci. As use herein to "protect against infections" means to prevent, reduce the likelihood of, or ameliorate the pathogenic effects of, an infection caused by a Streptococcus. In one embodiment, isolated Spa antigens of the this invention are formulated in a therapeutically suitable medium and used to elicit cross-protective antibodies in an animal. Spa antigens include the aforementioned proteins, polypeptides or peptides whether naturally occurring, synthetic, or produced by expression of a recombinant DNA vector containing a nucleic acid sequence encoding a Spa antigen, which are reactive with antibodies raised against the purified Spa protein or peptides of the present invention.

In a typical embodiment, the therapeutic composition containing a Spa antigen comprises an antigen that is protective against a multiple Streptococci serotypes. In a more typical embodiment the therapeutic composition contains an opsonic epitope that is cross protective against group A Streptococci including Type 28, Type 3, Type 18 Streptococci. Such a composition is expected to be considerably less complex than previous compositions comprised of M-protein or derivative thereof, for example, compositions where limited amino-terminal fragments of different M proteins are linked in tandem to evoke protective immune responses against each serotype represented in the vaccine. While such an approach has the advantage of limiting the amount of M protein contained in a vaccine, a large number of combinations must be provided because each M protein fragment is type-specific. This necessitates the development of relatively complex vaccines to prevent the majority of Streptococcal infections in a given population or geographic region. In contrast, the Spa antigens and antibodies, and nucleic acids of the present invention can be used to provide broad protection and/or can be used in combination with M-proteins and peptides to enhance the effectiveness of protection provided by either protein alone.

In this aspect, the present invention provides compositions and methods comprising one or more of the above-described Spa antigens or antibodies thereto in combination with one or more pharmaceutically or physiologically acceptable carriers, adjuvants, binders or diluents. Compositions containing antigens can be used to elicit

or enhance an immune response in a recipient animal, which is preferably a human being, and preferably elicits or enhances a protective or partially protective immunity against *Streptococcus*, or against a host cell expressing a surface antigen comprised of a Spa antigen of the present invention. Compositions containing antibodies may be used  
5 to diagnose or treat infections caused by *Streptococci*.

Preferably, such carriers, adjuvants, binders or diluents are nontoxic to recipients at the dosages and concentrations employed. Ordinarily, the preparation of such compositions entails combining the an antigen or antibody of this invention with buffers, antioxidants such as ascorbic acid, low molecular weight (less than about 10  
10 residues) polypeptides, proteins, amino acids, carbohydrates including glucose, sucrose or dextrans, chelating agents such as EDTA, glutathione and other stabilizers and excipients. Neutral buffered saline or saline mixed with nonspecific serum albumin are exemplary appropriate diluents. Examples of adjuvants include alum or aluminum hydroxide for humans.

15 It will be evident in light of the present specification to those in the art that the amount and frequency of administration can be optimized in clinical trials, and will depend upon such factors as the disease or disorder to be treated, the degree of immune inducement, enhancement, or protection required, and many other factors.

In one embodiment, the therapeutic composition is administered orally,  
20 and a Spa antigen of the invention is taken up by cells, such as cells located in the lumen of the gut. Alternatively, the therapeutic composition can be parenterally administered via the subcutaneous route, or via other parenteral routes. Other routes include buccal/sublingual, rectal, nasal, topical (such as transdermal and ophthalmic), vaginal, pulmonary, intraarterial, intramuscular, intraperitoneal, intraocular, intranasal  
25 or intravenous, or indirectly. The Spa compositions of the present invention can be prepared and administered as a liquid solution, or prepared as a solid form (e.g., lyophilized) which can be administered in solid form or resuspended in a solution in conjunction with administration.

Depending upon the application, quantities of Spa antigen in the  
30 composition will vary generally from about 0.1  $\mu$ g to 1000 mg, typically from about 1  $\mu$



g to 100 mg, more typically from about 10 µg to 10 mg, and usually from about 100 µg to 1 mg, in combination with the physiologically acceptable carrier, binder or diluent. Booster immunizations can be given at 2-6 weeks intervals.

The Spa antigens of this invention may also be used with immunological carriers in conjugate vaccines. Preferably, a beneficial carrier includes another polypeptide that has immunostimulant but does not have immunosuppressive effects. Such carriers may be used to elicit an increased immune response to the conjugated molecule. The *spa* gene products of this invention may also be used as carriers (in conjugates or fusion proteins) in combination with other antigens so as to provide compositions providing further protection elicited by epitopes additional to those contained on Spa, for example, M protein polypeptides may.

A further aspect of the present invention is protection from Streptococcus infections by treatment of an animal, preferably an animal and most preferably a human with a therapeutic composition containing the Spa antigens or antibodies of the present invention. As used herein, "protection" means to prevent or to reduce the severity of a disease associated with a Streptococcus infection. In a typical practice, the Spa antigens of the present invention provide protection against multiple serotypes of Streptococci. In one embodiment, protection is provided against multiple stereotypes of group A Streptococci. The capacity for protection against multiple serotypes is illustrated for example in Table 5 (Example 6) where it is shown that a composition comprised of crude surface peptides containing a Spa polypeptide or an isolated Spa polypeptide from a Type 18 Streptococci elicited production of antisera that provided opsonic protection against Type 3, Type 18 and Type 28 Streptococci. In addition, Tables 3 and 4 (Example 5) show that antisera raised against the 23 amino acid N terminus of a Spa polypeptide displayed similar opsonization and bactericidal activity TO antisera against the crude peptides and isolated Spa polypeptides.

## VII. Therapeutic Methods

Accordingly, another aspect of the present invention is therapeutic methods for protecting an animal against a Streptococcus infection that includes the

step of administering to the animal at least one of the aforementioned therapeutic compositions. Typically, administering a therapeutic compositions containing Spa antigens elicits opsonic antibodies in the animal. Similarly, administering a composition containing antibodies raised against Spa antigens will provide opsonic antibodies which facilitate a phagocytic responses in the animal. In a preferred embodiment, protection is provided against multiple serotypes of Streptococcus. In a related embodiment, the therapeutic composition is administered by at least one of oral administration, intranasal administration, intramuscular vaccination, subcutaneous vaccination, or vascular vaccination. In another preferred embodiment, the therapeutic method is used with the human.

The compositions and methodologies described herein are suitable for a variety of uses. To this end, the following examples are presented for purposes of illustration, not limitation.

## EXAMPLES

15

### EXAMPLE 1

#### CONSTRUCTION AND CHARACTERIZATION OF AN M-NEGATIVE MUTANT (M18 $\Omega$ )

Bacterial strains. The parent Type 18 Streptococcal strain 87-282, was obtained from Dr. P. Patrick Cleary at the University of Minnesota. The M3 strain (3375) was provided by Dr. James Musser, Baylor College of Medicine, Houston, TX. The M28 strain (S2356) was from our laboratory collection.

The new Streptococcal protective antigen was discovered during studies of an M-negative mutant of Type 18 Streptococci. Briefly, as discussed in more detail below, the M-negative M18 strain was constructed by interrupting the *emm18* gene with an  $\Omega$ -element. Southern blot analyses of chromosomal DNA from the M18 and M18 $\Omega$  strains that was probed with (Km2 and *emm18* fragments and PCR analyses using primers from the *emm* gene and the  $\Omega$ -element revealed that there was a single copy of the  $\Omega$ -element inserted ~140 bp beyond the start codon of the *emm18* gene.

A fragment of the *emm18* gene was initially cloned by PCR using a forward primer that copied the 3' end of the *emm18* gene and a reverse primer that was specific for this subfamily (SF 3) of *emm*-like genes. The purified PCR product was ligated into pKK223-3 and the insert was sequenced by standard methods. The intact  
5 *emm18* gene was later cloned using a reverse primer that copied the 5' end of the *scpA* gene and the purified PCR product was ligated into pQE-30 (Qiagen, Chatsworth, CA). The recombinant Emm18 protein was purified by affinity chromatography over a nickel column according to the instructions provided by Qiagen.

Insertion of the  $\Omega$  -interposon into *emm18* and transformation of Type  
10 18 Streptococci was accomplished essentially as previously described for Type 24 Streptococci. Briefly, *emm18* was ligated into pKK223-3 and then cut with XhoI, which recognizes a single site between bases 136 and 141 of the *emm18* gene. The ends were repaired with Klenow fragment. Plasmid pBR322- $\Omega$ ,Km2 was digested with SmaI and the  $\Omega$ ,Km2 fragment was purified from a 0.8% agarose gel and ligated into  
15 the cut *emm18* gene. The resulting plasmid, pKKM18 $\Omega$ , was electroporated into Type 18 Streptococci. One kanamycin-resistant colony, designated M18 $\Omega$ , was selected for further study.

To confirm that the *emm18* gene was not expressed in the M18 $\Omega$  strain, immunoblots were performed using extracts of whole bacteria and rabbit antisera  
20 evoked by purified recombinant M18 (rM18), a synthetic peptide of M18, SM18(1-30), and a synthetic peptide SM5(265-291), which copies the C-repeat domain of Type 5 M protein that is common to all M proteins (Figure 1). Anti-rM18 reacted with a triplet of proteins extracted from the parent strain, the largest of which had an apparent M.W. of ~43 kDa (Figure 1, lane A). The immunoreactive proteins with lower M.W. are  
25 presumably degradation products of M18 that were present in the crude extracts of whole bacteria. There was no reaction of rM18 antiserum with the extract from the M18 $\Omega$  mutant (Figure 1, lane B). Anti-SM18(1-30) reacted only with proteins in extracts from the parent strain (Figure 1, lane C) and the pattern was identical to that observed with antiserum against rM18. Interestingly, antiserum against the C-repeat  
30 peptide of M protein, SM5(265-291), reacted only with an extract from the parent strain

(Figure 1, lane E) and not with an extract from the mutant (lane F), suggesting that the mutant did not express another M or M-like protein containing these shared repeating epitopes. These data, taken together with the results of the Southern blots and PCR, indicate that the  $\Omega$  element was inserted in the *emm18* gene and the M18 protein was not expressed by M18 $\Omega$ .

Western blots were performed using extracts of intact Streptococci and purified proteins as previously described. In some experiments using purified recombinant Emm18 protein, the nitrocellulose membranes were first incubated in buffer containing 10% normal human serum to block nonspecific binding of immunoglobulins.

For southern blots, Streptococcal chromosomal DNA was digested with BsaH I and electrophoresed in a 1% agarose gel. The DNA fragments were transferred to a nylon membrane (Sigma) and probed with digoxigenin-labeled (Km2 fragment or *emm18* according to instructions provided by the manufacturer (Boehringer Mannheim, Indianapolis, IN).

## EXAMPLE 2

### GROWTH IN BLOOD AND MOUSE VIRULENCE OF M18 AND M18 $\Omega$

A. Growth in non-immune human blood. The virulence of the M-negative mutant of Type 18 Streptococci was first assessed by its ability to grow in nonimmune human blood (Table 1). Streptococci were grown to early log-phase in Todd-Hewitt broth and the inoculum indicated was added to 0.45 ml normal, heparinized human blood that did not contain M18 antibodies. The mixture was rotated end-over-end at 37°C for 3 hr. Organisms surviving were quantitated on pour plates of sheep's blood agar using an aliquot of the mixture. The parent strain of M18 grew to just over 8 generations after a three-hour rotation in blood. The M18 $\Omega$  mutant grew to approximately 7.5 generations in the same assay.

Table 1.

**Growth in human blood of M18 and M18 $\Omega$  Streptococci.**

| Organism     | CFU surviving 3 hr rotation<br>(# of generations) |                            |
|--------------|---|----------------------------|
|              | inoculum: 45                                      | inoculum: 15               |
| M18          | 12,550 (8.1)                                      | 4,800 (8.3)                |
| M18 $\Omega$ | inoculum: 55<br>9,940 (7.3)                       | inoculum:20<br>4,210 (7.6) |

5

B. Intraperitoneal challenge infections. The most stringent laboratory assay for virulence is intraperitoneal challenge infections of nonimmune mice. Briefly, four groups of six Swiss white mice each were challenged with 10-fold increasing inocula, ranging from  $2.7 \times 10^4$  to  $2.7 \times 10^7$  CFU of either M18 or M18 $\Omega$ . Deaths were recorded for seven days following challenge infections. The LD50 was determined by the method of Reed and Muench after using 10-fold increasing doses of each organism. The LD50 of the parent M18 strain was  $0.73 \times 10^5$  and of the M18 $\Omega$  was  $1.26 \times 10^5$ . Of 24 mice challenged with each organism, 8 challenged with M18 died while 7 challenged with M18 $\Omega$  died. Organisms recovered from the spleens of mice that succumbed to challenge infections with M18 $\Omega$  were kanamycin-resistant and M18 negative, indicating that there was no reversion to the parent phenotype *in vivo*. These results demonstrated that the expression of M18 was not required for virulence of Type 18 Streptococci.

20

## EXAMPLE 3

OPSONIZATION OF M18 AND M18 $\Omega$  PARTICLES

## USING ANTISERA AGAINST CRUDE SURFACE PEPTIDES

25

Interruption of *emm18* expression could have resulted in a mutant that was virulent and did not express a protective antigen, or alternatively, one that

expressed a second protective antigen on its surface. In order to assess the possibility of the latter, *in vitro* opsonization experiments were performed to determine whether M18 $\Omega$  expressed a surface antigen that contained opsonic epitopes. Early log-phase cultures of Streptococci were added to 0.1 ml of test serum and incubated for 15 min. at ambient temperature. To this was added 0.4 ml of normal, heparinized human blood and the entire mixture was rotated end-over-end for 45 min. at 37°C. At the end of the rotation, a drop of each mixture was used to make thin smears on microscope slides. After staining the slides with Wright's stain, the percentage of neutrophils with associated Streptococci (either ingested or attached) was estimated by counting at least 50 consecutive neutrophils. Anti-rM18, rabbit antiserum against intact, recombinant Type 18 M protein; anti-SM18(1-30), rabbit antiserum against a synthetic peptide that copied the N-terminal 30 amino acids of M18 linked to KLH; anti-crude pep M18, rabbit antiserum against a partially purified pepsin extract of whole Type 18 Streptococci. Experiments were repeated at least three times with similar results.

The bactericidal activity of test antisera was determined using a similar assay except that fewer Streptococci were added to the mixture, which was rotated for 3 hr. at 37°C. At the end of the rotation, 0.1 ml aliquots were added to sheep blood agar and pour plates were made to quantitate viable bacteria. Results shown in Table 2 below are from one representative experiment. Briefly, only the M18 parent strain was opsonized by antisera against SM18(1-30) or recombinant M18. The association of M18 $\Omega$  with PMNs remained at baseline levels in the presence of both of these antisera. Antiserum raised in rabbits against a crude pepsin extract of the M18 $\Omega$  strain, however, opsonized both the parent and the M-negative mutant (Table 2). This antiserum was used in subsequent experiments to identify and purify the putative new protective antigen of Type 18 Streptococci.

Table 2.  
**Opsonization of M18 and M18 $\Omega$  by rabbit antisera**  
**against recombinant M18, S-M18(1-30), and crude pep M18.**

| Antiserum          | Percent neutrophils with associated Streptococci |              |
|--------------------|--|--------------|
|                    | M18  | M18 $\Omega$ |
| Pre-pool           | 2  | 8            |
| Anti-rM18          | 92   | 14           |
| Anti-SM18(1-30)    | 98   | 8            |
| Anti-crude pep M18 | 96   | 88           |

5

#### EXAMPLE 4

##### IDENTIFICATION, PURIFICATION, AND AMINO-ACID SEQUENCE ANALYSIS OF SPA.

As is discussed in more detail in the following example, peptide  
 10 fragments from the surface of M18 $\Omega$  were extracted using dilute solutions of pepsin at suboptimal pH. The extract was precipitated in 60% saturated ammonium sulfate, dialyzed extensively against distilled water, and then lyophilized. The mixture of surface proteins and peptides is referred to as crude pep M18 $\Omega$ .

More specifically, as described above in Example 3, Spa was identified  
 15 in the crude pepsin extract by opsonization inhibition assays. The crude pep M18 $\Omega$  was separated by SDS-PAGE on a preparative 10% gel using reducing conditions. The entire gel was electroblotted to nitrocellulose paper and each end was cut vertically and stained with Coomassie blue. The center section of the nitrocellulose paper was cut into horizontal strips approximately 8-10mm in width. Each strip was then used to  
 20 absorb rabbit antiserum raised against the crude pep M18 $\Omega$  for 2 hours at 37°C. One section of the nitrocellulose paper was western blotted with pep M18 $\Omega$  antiserum to identify immunoreactive bands. Another section was cut into horizontal strips that were used to absorb opsonic antibodies in the pep M18 $\Omega$  antiserum. The pep M18 $\Omega$  extract contained a protein with an apparent M.W. of 24kDa (Spa) that absorbed the majority  
 25 of the opsonic antibodies in the pep M18 $\Omega$  antiserum (Figure 2).

Opsonization assays were performed using absorbed serum samples and unabsorbed serum, as described above in Example 3. Once the opsonic-inhibitory peptide had been identified in the crude pepsin extract, it was purified by ammonium sulfate precipitation and preparative gel electrophoresis (Prep Cell, model 491, Bio-  
5 Rad, Richmond, CA).

The purified Spa migrated as a single band, as assessed by SDS-PAGE, with a M.W. of 24kDa (Figure 3, Lane B). The purified Spa protein was electrophoretically transferred to a PVDF membrane and submitted to the Protein and Nucleic Acid Facility, Beckman Center, Stanford University Medical Center for N-  
10 terminal sequencing by Edman degradation. The sequence of an internal peptide of Spa was also determined in the Stanford University Facility. The intact protein on PVDF was digested with LysC protease, 0.25 (mol/ml, at 37°C overnight). The resultant peptides were purified by HPLC on a Vydac C18 column. Selected fractions were assessed for purity by mass spectroscopy and one peptide with a mass of 1249 Daltons  
15 was selected for N-terminal sequencing.

Edman degradation of the purified protein revealed the sequence of the first 23 amino acids (N-terminus) to be:

20 DSVSG LEVAD PSDSK KLIEL GLA (SEQ ID NO:3)

In addition, an internal peptide purified from a LysC digest of the purified Spa contained the amino-terminal sequence:

25 YRLDS ESHLK. (SEQ ID NO:8)

## EXAMPLE 5

### IDENTIFICATION OF OPSONIC EPITOPES OF SPA

Rabbit antisera was prepared against the synthetic peptide SM18(1-30)C  
30 against recombinant M18, which was purified from periplasmic extracts of *E. coli*, and against purified Spa.



To directly assess the presence of bactericidal epitopes in Spa, rabbits were immunized with 100 µg of the purified protein in CFA at time 0, 4 weeks, and 8 weeks. Sera from all three immunized rabbits obtained 10 weeks after the first injection contained antibodies that opsonized the M18 parent and M18Ω (Table 3). None of the  
5 Spa antisera cross-reacted with purified recombinant M18 or purified recombinant Emm18, as determined by ELISA

To confirm the presence of opsonic epitopes within the covalent structure of Spa, a peptide, S-*Spa18*(1-23)C, copying the N-terminal 23 amino acids of the purified 24 kDa fragment was chemically synthesized. The peptide was covalently  
10 linked to KLH and three rabbits were immunized with 100 µg doses using the same schedule described above. Anti-Spa, rabbit antiserum against the purified Streptococcal protective antigen; anti-S-*Spa*(1-23)C, rabbit antiserum against a synthetic peptide that copied the N-terminal 23 amino acids of Spa linked to KLH; anti-rM18, rabbit antiserum against intact, recombinant Type 18 M protein were used. Details of the  
15 assay are provided in Example 3. Experiments were repeated at least three times with similar results. Data presented are from one representative experiment. Briefly, serum from all three rabbits opsonized both the parent and M18Ω strains of group A Streptococci (Table 3), confirming the presence of opsonic epitopes within this limited region of Spa. The antiserum against the synthetic peptide of Spa was also used to  
20 identify the native protein in phage lysin extracts of M18Ω. The S-*Spa18*(1-23)C antiserum reacted with a single protein in the lysin extract with an apparent M.W. of 50kDa (Figure 3D), suggesting that the pepsin-derived Spa was a fragment of the larger native protein.

**Table 3.**  
**Opsonization of Type 18 Streptococci by rabbit antisera against purified Spa and a synthetic peptide of Spa.**

| Antiserum:        | Percent neutrophils<br>with associated Streptococci: |      |
|-------------------|--|------|
|                   | M18  | M18Ω |
| NRS               | 4  | 6    |
| anti-Spa          | 100  | 100  |
| anti-S-Spa(1-23)C | 72   | 100  |
| anti-rM18         | 96   | 16   |

5

The results of the opsonization assays were confirmed by indirect bactericidal tests as described in Example 3. Anti-rM18, rabbit antiserum against intact, recombinant Type 18 M protein; anti-crude pep M18, rabbit antiserum against a partially purified pepsin extract of whole Type 18 Streptococci; anti-Spa, rabbit antiserum against the purified Streptococcal protective antigen were used. The results provided in Table 4 show the Spa antiserum was bactericidal against both M18 and M18Ω while antiserum against rM18 was bactericidal against only the parent M18 strain and not against M18Ω.

**Table 4.**  
**Bactericidal activity of rabbit antisera against rM18, a crude pepsin extract of Type 18 Streptococci, and purified Spa.**

| Antiserum:          | CFU surviving a 3 hour rotation |                      |
|---------------------|---------------------------------|----------------------|
|                     | M18<br>Inoculum: 21             | M18Ω<br>Inoculum: 32 |
| Normal Rabbit Serum | >10,000                         | >10,000              |
| anti-rM18           | 460                             | >10,000              |
| anti-crude pep M18  | 355                             | 15                   |
| anti-Spa            | 230                             | 0                    |

15

## EXAMPLE 6

OPSONIZATION OF HETEROLOGOUS SEROTYPES OF  
GROUP A STREPTOCOCCI BY SPA ANTISERUM

5 To determine whether Spa evoked opsonic antibodies against serotypes of group A Streptococci other than Type 18, opsonization assays were performed with antisera against purified Spa or against the pep M18 $\Omega$  and a series of selected Streptococci (Table 5). Both antisera opsonized Type 3 and Type 28 Streptococci, in addition to Type 18 organisms. Serotypes tested that were not opsonized by either  
10 antiserum were M1, M2, M5, M6, M13, M14, M19, and M24, all of which were from our laboratory collection. The anti-S-*Spa*18(1-23)C antisera did not opsonize Types 3 or 28 Streptococci, indicating that this limited region of Spa does not contain cross-opsonic epitopes.

Table 5.

15 **Opsonization of heterologous serotypes of group A Streptococci by rabbit antisera against purified Spa and a crude pepsin extract of M18 $\Omega$ .**

| Serotype<br>(strain) | Percent neutrophils with associated<br>Streptococci in the presence of: |                                |           |          |
|----------------------|---|--------------------------------|-----------|----------|
|                      | Preimmune   | Anti-crude<br>pep M18 $\Omega$ | Preimmune | Anti-Spa |
| M18 (282)            | 0   | 100                            | 6         | 100      |
| M3 (3375)            | 14  | 88                             | 8         | 56       |
| M28 (S2356)          | 20  | 72                             | 0         | 36       |

20

## EXAMPLE 7

NUCLEIC ACID AND AMINO ACID SEQUENCE  
OF A CLONED FRAGMENT OF THE *spa*18 GENE

A fragment of the *spa*18 gene was cloned using PCR and degenerate inosine-containing oligonucleotide primers based on the N-terminal peptide sequence  
25 and the sequence of an internal peptide purified from a LysC digest of Spa. The forward set of primers derived from the N-terminal sequence of Spa from amino acid

residues 7-11 contained the sequence GAR GTI GCI GAY CC (SEQ. ID NO: 6) The reverse primers, from the N-terminal sequence of the internal peptide, contained the sequences RTG IGA YTC RCT RTC and RTG RCT YTC IGA RTC (SEQ. ID NO: 7). Nucleotide abbreviations are according to the UUPAC code for nucleic acids. PCR was performed as previously described using the chromosomal DNA from Type 18 Streptococci as the template. The forward primer in combination with the second reverse primer listed above resulted in a single PCR product of 336 bp, which was ligated into pCR2.1-TOPO (Invitrogen, Carlsbad, CA). DNA sequencing was performed by automated techniques in the University of Tennessee Molecular Resources Center using primers from the 5' and 3' flanking ends of the plasmid. The identity of the *spa* sequence was confirmed by comparing the translated DNA sequence to the amino acid sequence of Spa that was not used to construct the degenerate PCR primers.

The 336 bp PCR product and the translated amino acid sequence contained residues 12-23 of the sequence derived from the Spa protein (Figure 4), confirming that the DNA was a fragment of *spa18*. A search of the current entries in GenBank and the Type 1 Streptococcal genome sequence data base revealed that the *spa18* gene fragment did not share sequence homology with any known proteins, suggesting that Spa is a new protective antigen of group A Streptococci.

Standard molecular biology techniques were used to obtain a full-length cDNA encoding a *spa* protein. The sequences for the full-length cDNA and encoded protein are depicted in Figures 5 and 6, respectively. The full-length protein includes a 37 residue signal peptide that is cleaved to form a mature *spa* polypeptide having the same N-terminus as the 23 residue peptide identified as SEQ ID NO:3.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## CLAIMS

1. A Spa polypeptide isolated from a *Streptococcus* species comprising a polypeptide having at least 50% amino acid sequence identity to SEQ. ID NOS:2 or 5.
2. The isolated Spa polypeptide of claim 1 wherein the *Streptococcus* is a member of the species *Streptococcus pyogenes*.
3. The isolated Spa polypeptide of claim 2 wherein the *Streptococcus* is a group A serotype selected from Type 18, Type 3, and Type 28.
4. The isolated Spa polypeptide of claim 3 wherein the group A serotype is Type 18.
5. The isolated Spa polypeptide of claim 3 wherein the group A serotype is Type 3.
6. The isolated Spa polypeptide of claim 3 wherein the group A serotype is Type 23.
7. An isolated Spa polypeptide comprising the amino acid sequence of SEQ. ID NOS: 2 or 5 or variants thereof, wherein the variants include amino acid sequences having conservative amino acid substitutions or having at least 90% sequence identity to SEQ. ID NOS: 2 or 5.
8. The isolated Spa polypeptide according to any one of claims 1-7 wherein the Spa polypeptide contains an opsonic epitope.

9. The isolated polypeptide of claim 8 wherein the opsonic epitope comprising contiguous amino acids from a portion of an N-terminus of the polypeptide which is exposed on an outside surface of a cell when the polypeptide is expressed in the cell.
10. The isolated Spa polypeptide of claim 9 wherein the opsonic epitope comprising at least 23 contiguous amino acids of the N-terminus of the polypeptide.
11. A peptide comprised of at least 23 amino acids of the N-terminus of a Spa polypeptide according to claim 1.
12. The peptide according to claim 11 comprising the amino acid sequence of SEQ. ID NO:3 or variants thereof, wherein the variants comprise amino acid sequences having conservative amino acid substitutions or having at least 80% sequence identity to SEQ. ID NO: 3.
13. An immunogen for protecting an animal against a Streptococcus infection comprising a Spa polypeptide according to any one of claims 1-10.
14. An immunogen for protecting an animal against a Streptococcus infection comprising a peptide according to any one of claims 11 or 12.
15. An immunogen for protecting an animal against a Streptococcus infection comprising a peptide that contains at least 8 contiguous amino acids from a peptide according to any one of claims 11 or 12.
16. The immunogen according to claim 15 wherein said immunogen provides cross protection against more than one serotype of Streptococci.
17. The immunogen of claim 16 wherein the cross-protection is provided against Streptococci of the group A serotype.

18. The immunogen of claim 17 wherein cross protection is provided against group A Streptococci selected from Type 3, Type 18 and Type 28 Streptococci.

19. An antibody that specifically binds to an epitope present on a Spa polypeptide according to claim 1.

20. An antibody that specifically binds to an epitope present on a peptide according to claim 11.

21. The antibody of claim 19 wherein the epitope comprises at least 8 contiguous amino acids of the Spa polypeptide.

22. The antibody of claim 20 wherein the peptide comprises at least 8 contiguous amino acids of the N-terminus of the Spa polypeptide.

23. The antibody according to claim 19 wherein the antibody does not bind to an M protein of a Streptococcus species.

24. The antibody according to claim 20 wherein the antibody does not bind to an M protein of a Streptococcus species.

25. An isolated nucleic acid molecule comprising SEQ ID NOS: 1 or 4, or a sequence that encodes a Streptococcus Spa polypeptide according to claim 1, or a complement of said nucleic acid molecule.

26. An isolated nucleic acid molecule comprising a sequence selected from SEQ. ID NOS: 1 or 4, a complement of SEQ. ID NOS: 1 or 4, or variants thereof, wherein the variants are selected from sequences that encode the polypeptide of SEQ. ID NOS: 2 or 5 which are degenerate to SEQ. ID NOS: 1 or 4 because of the genetic code; sequences that encode a polypeptide which has conservative amino acid substitutions to the polypeptide of

SEQ. ID NOS: 2 or 5, or sequences that encode a polypeptide that is at least 50% identical to SEQ. ID NOS: 2 or 5.

27. An isolated nucleic acid molecule comprising a sequence that hybridizes to the nucleic acid molecule of claim 26 under conditions of moderate stringency.

28. An isolated nucleic acid molecule comprising a sequence that encodes an opsonic epitope from a Spa polypeptide comprising a polypeptide having at least 50% amino acid sequence identity to SEQ. ID NOS:2 or 5.

29. The nucleic acid molecule of claim 28 wherein the sequence encodes a fusion polypeptide containing the opsonic epitope fused to at least one other peptide sequence.

30. The nucleic acid molecule of claim 29 wherein the other peptide sequence comprises a tag sequence that facilitates isolation of the fusion polypeptide from a cellular extract.

31. The nucleic acid molecule of claim 29 wherein the other peptide sequence is a carrier protein.

32. A vector comprising the isolated nucleic acid molecule of any one of claims 25-31 operably linked to a promoter wherein said vector expresses a polypeptide encoded by the isolated nucleic acid when the vector is introduced into a host cell.

33. A host cell carrying the vector according to claim 32.

34. A therapeutic composition for protecting an animal from a Streptococcus infection comprising a biologically acceptable diluent and an effective amount of an immunizing agent selected from:



a) a Spa polypeptide isolated from Streptococcus comprising a polypeptide having at least 50% amino acid sequence identity to SEQ. ID NOS:2 or 5;

b) an immunogen comprised of an opsonic epitope obtained from the Spa polypeptide of a);

c) a host cell that expresses an opsonic epitope obtained from the Spa polypeptide of a); or

d) an antibody that specifically binds to the Spa polypeptide of a).

35. The composition of claim 34 wherein the immunizing agent is a Spa polypeptide according to claim 1.

36. The composition of claim 34 wherein the immunizing agent is a peptide according to claim 11.

37. The composition of claim 34 wherein the immunizing agent is an immunogen according to claim 15.

38. The composition of claim 37 wherein the immunizing agent is conjugated to a carrier.

39. The composition of claim 34 wherein the immunizing agent is a host cell according to claim 33.

40. The composition of claim 34 wherein the immunizing agent is an antibody according to claim 19.


41. A therapeutic method for protecting an animal against a Streptococcus infection comprising the step of administering to the animal the therapeutic composition of claim 34, wherein administering the therapeutic composition elicits opsonic antibodies in the animal.

42. The method of claim 41 wherein protection is provided against more than one serotype of Streptococci.

43. The method of claim 41 wherein the therapeutic composition is administered by oral administration, intranasal administration, intramuscular administration, subcutaneous administration, or vascular vaccination.


44. The method of claim 41 wherein the animal is a human.

1/7




*Fig. 1*

2/7

*Fig. 2*

3/7



*Fig. 3*

4/7

|   |     |
|---|-----|
| GAA GTG GCG GAC CCC TCT GAT AGT AAG AAA CTT ATT GAG TTA GGT TTG | 48  |
| Glu Val Ala Asp Pro Ser Asp Ser Lys Lys Leu Ile Glu Leu Gly Leu |     |
| 1 5 10 15   |     |
| GCT AAA TAC CTT AAT GAT AAA TTA CCC TTT AAA ACT AAA GAA GAT TCA | 96  |
| Ala Lys Tyr Leu Asn Asp Lys Leu Pro Phe Lys Thr Lys Glu Asp Ser |     |
| 20 25 30  |     |
| GAG ATT TTA TCA GAG TTA CGT GAT GTA TTA AAA AAT GCT AAT CCA GAA | 144 |
| Glu Ile Leu Ser Glu Leu Arg Asp Val Leu Lys Asn Ala Asn Pro Glu |     |
| 35 40 45  |     |
| ACA TTA AAA AGT TTA CTT AAT GGT ATG GAT CAA GGA CAT ATA TCA TTT | 192 |
| Thr Leu Lys Ser Leu Leu Asn Gly Met Asp Gln Gly His Ile Ser Phe |     |
| 50 55 60  |     |
| TCT GAT AGA AAT AAT CGC TAC AAC CGT TTA TCT CAA TAT ATA AAT AGT | 240 |
| Ser Asp Arg Asn Asn Arg Tyr Asn Arg Leu Ser Gln Tyr Ile Asn Ser |     |
| 65 70 75 80   |     |
| TTT AGA AAA GAT GAT GAT GAC TAT CTA CAT AAT GGA TAT TCT TTA NGA | 288 |
| Phe Arg Lys Asp Asp Asp Tyr Leu His Asn Gly Tyr Ser Leu Xaa     |     |
| 85 90 95  |     |
| AGT TTA GTG ATT GAA GCA ATT AAA TAC CGT TTA GAT AGC GAA TCC CAT | 336 |
| Ser Leu Val Ile Glu Ala Ile Lys Tyr Arg Leu Asp Ser Glu Ser His |     |
| 100 105 110   |     |

*Fig. 4*

5/7

```

      10      20      30      40
      *      *      *      *      *      *      *      *
ATA ATA TAC ATT CTT TCT TAT TAA ATA AAA ATA ACA ATG TAC TAC ATA
50      60      70      80      90
      *      *      *      *      *      *      *      *
AAG AAG TTT CTG CCA TTA AAA TAA AAG CAC CAT GAG ACT ATA ATA GTA
100     110     120     130     140
      *      *      *      *      *      *      *      *
TGG TAA AAC AAA AAA GTA TGC CCA TAA CGG GTA GAG AGG AAT TGA CAT
150     160     170     180     190
      *      *      *      *      *      *      *      *
ATG TTT TTG AGA AAT AAA AAG CAA AAA TTT AGC ATC AGA AAA CTA AGT
200     210     220     230     240
      *      *      *      *      *      *      *      *
GCT GGT GCA GCA TCA GTA TTA GTT GCA GCA AGT GTG TTG GGA GGG GGA
250     260     270     280
      *      *      *      *      *      *      *      *
GTA AGT GCG TAT GCA GAT TCA GTA AGT GGA TTA GAG GTG GCA GAC CCC
290     300     310     320     330
      *      *      *      *      *      *      *      *
TCT GAT AGT AAG AAA CTT ATT GAA TTA GGT TTG GCT AAA TAC CTT AAT
340     350     360     370     380
      *      *      *      *      *      *      *      *
GAT AAA TTA CCC TTT AAA ACT AAA GAA GAT TCA GAG ATT TTA TCA GAG
390     400     410     420     430
      *      *      *      *      *      *      *      *
TTA CGT GAT GTA TTA AAA AAT GCT AAT CCA GAA ACA TTA AAA AGT TTA
440     450     460     470     480
      *      *      *      *      *      *      *      *
CTT AAT GGT ATG GAT CAA GGA CAT ATA TCA TTT TCT GAT AGA AAT AAT
490     500     510     520
      *      *      *      *      *      *      *      *
CGC TAC AAC CGT TTA TCT CAA TAT ATA AAT AGT TTT AGA AAA GAT GAT
530     540     550     560     570
      *      *      *      *      *      *      *      *
GAT GAC TAT CTA CAT AAT GGA TAT TCT TTA GGA AGT TTA GTG ATT GAA

```

*Fig. 5A*

6/7

```

580      590      600      610      620
*      *      *      *      *      *      *      *
GCA ATT AAA TAC CGT TTA GAT AGT GAG TCA CAT CTA AAG GAA GAA TTA
630      640      650      660      670
*      *      *      *      *      *      *      *
CTT AAA CAG ACT GCA GAA CTT GAG CAA CGT AAG AAT GCA GAA GTT GAT
680      690      700      710      720
*      *      *      *      *      *      *      *
TTA AAA TCT GAA AAA AAG AGA CTT GAA GCG CAA ATA NAA AAA GTA GGA
730      740      750      760
*      *      *      *      *      *      *      *
TAT GAT ATT GCT AAT AAA CAG CAA GAA TTA GAA AAA GCG CGT TCA GAT
770      780      790      800      810
*      *      *      *      *      *      *      *
CAA AAA GAG TTA AGT GAA TCT ATT CAA AAA TTA ACG TCA CGA TTT AAA
820      830      840      850      860
*      *      *      *      *      *      *      *
AAA GAA AGT GAT GCT AAA CAA AAA GAA CTA GAT GAA GCT AAG GCG GCA
870      880      890      900      910
*      *      *      *      *      *      *      *
AAT AAA TCT CTT TCA GAG TCA GCA ACA AAA ACA TTA GCT AGA TCA TCT
920      930      940      950      960
*      *      *      *      *      *      *      *
AAG ATA ACT AAT GAA TTA AAG GAT AAG TTG GCG GCT TCA GAA AAA GAT
970      980      990      1000
*      *      *      *      *      *      *      *
AAA AAT CGT GCA TTT CAA GTT TCT TCA GAG CTA GCT AAT AAG TTG CAT
1010      1020      1030      1040      1050
*      *      *      *      *      *      *      *
GAA ACA GAA ACT AGT CGT GAT AAG GCT TTA GCA GAA TCA AAA GAA TTA
1060      1070      1080      1090      1100
*      *      *      *      *      *      *      *
GCA GAT AAA TTG GCA GTT AAA ACA GCA GAA GCT GAA AAG TTA ATG GAA
1110      1120      1130      1140      1150
*      *      *      *      *      *      *      *
AAC GTT GGT AGT CTA GAC CGC TTG GTA GAG TCT GCA AAA CGT GAA ATG
1160      1170      1180      1190      1200
*      *      *      *      *      *      *      *
GCT CAA AAA TTA GCA GAA ATT GAC CAA TTA ACT GCT GAT AAG GCT AAG
1210      1220      1230      1240
*      *      *      *      *      *      *      *
GCT GAT GCA GAG CTT GCA GCT GCA AAT GAC ACC ATT GCA TCA CTT CAA

```

Fig. 5B



7/7

```

1250      1260      1270      1280      1290
*      *      *      *      *      *      *      *      *
ACA GAG CTA GAA AAA GTT AAG ACA GAG CTT GCT GTT TCA GAG CGC TTG
1300      1310      1320      1330      1340
*      *      *      *      *      *      *      *      *
ATC GAA TCA GGT AAA CGT GAA ATT GCT GAG CTT GAA AAA CAA AAA GAT
1350      1360      1370      1380      1390
*      *      *      *      *      *      *      *      *
GCT TCT GAT AAG GCT TTA GCA GAA TCA CAA GCT AAT GTA GCA GAG CTT
1400      1410      1420      1430      1440
*      *      *      *      *      *      *      *      *
GAA AAA CAA AAA GCA GCA TCA GAT GCT AAG GTA GCA GAG CTT GAA AAA
1450      1460      1470      1480
*      *      *      *      *      *      *      *      *
GAA GTT GAA GCT GCT AAA GCT GAG GTT GCA GAT CTT AAA GCA CAA TTA
1490      1500      1510      1520      1530
*      *      *      *      *      *      *      *      *
GCT AAG AAA GAA GAA GAG CTT GAA GCC GTT AAG AAA GAA AAA GAA GCG
1540      1550      1560      1570      1580
*      *      *      *      *      *      *      *      *
CTT GAA GCT AAG ATT GAA GAG CTC AAA AAA GCT CAT GCT GAG GAA CTT
1590      1600      1610      1620      1630
*      *      *      *      *      *      *      *      *
TCA AAA CTT AAA GAA ATG CTT GAG AAG AAA GAC CAT GCG AAT GCA GAT
1640      1650      1660      1670      1680
*      *      *      *      *      *      *      *      *
CTT CAA GCA GAA ATC AAC CGC TTG AAG CAA GAG CTA GCT GAC AGG ATT
1690      1700      1710      1720
*      *      *      *      *      *      *      *      *
AAG TCA TTG TCA CAA GGT GGT CGT GCT TCA CAA ACA AAC CCA GGC TCT
1730      1740      1750      1760      1770
*      *      *      *      *      *      *      *      *
ACA ACT GCT AAA GCA GGT CAA TTG CCA TCT ACT GGT GAG TCT GCT AAC
1780      1790      1800      1810      1820
*      *      *      *      *      *      *      *      *
CCA TTC TTC ACT ATT GCA GCT CTT ACC GTC ATC GCT GGT GCT GGT ATG
1830      1840      1850      1860      1870
*      *      *      *      *      *      *      *      *
GCT GTG GTG TCT CCT AAA CGC AAA GAA AAC TAA GCT CTT TCC TCT TTC

```

*Fig. 5C*

# INTERNATIONAL SEARCH REPORT

Int. l. Application No  
PCT/US 99/30807

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/31 C07K14/315 A61K39/09 C07K16/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|------------|--|-----------------------|
| X          | <p>M. MEEHAN ET AL: "Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with Streptococcus equi subsp. equi" MICROBIOLOGY, vol. 144, no. part4, April 1998 (1998-04), pages 815-1130, XP000906842</p> <p>-&amp; M. MEEHAN ET AL: "Streptococcus equi fibrinogen-binding protein (fbp) gene, complete cds" EMBL ADATABASE ENTRY ACCESSION NUMBER AF012927, July 1997 (1997-07), XP002137198</p> <p>" 64,7% identity over whole sequence ID no.5 "</p> <p>the whole document</p> <p style="text-align: center;">-/-</p> | 1,13,34               |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 May 2000

Date of mailing of the international search report

22/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Le Cornec, N

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/30807

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT |  |                       |
|--|--|-----------------------|
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
| X  | WO 98 01561 A (MEEHAN MARY CHRISTINE ;OWEN<br>PETER (IE); TRINITY COLLEGE DUBLIN (IE)<br>15 January 1998 (1998-01-15)<br>claims; figure 18<br>-----  | 1,13,34               |
| A  | WO 94 06421 A (UNIV TENNESSEE RES CORP)<br>31 March 1994 (1994-03-31)<br>claims<br>-----   | 1-43,45               |
| A  | WO 94 06465 A (UNIV TENNESSEE RES CORP)<br>31 March 1994 (1994-03-31)<br>the whole document<br>-----   | 1-43,45               |
| A  | J.D. CHAPPELL ET AL: "Demonstration of<br>protection in mice from a lethal challenge<br>of three M serotypes of Streptococcus<br>pyogenes using an M-negative vaccine"<br>VACCINE.,<br>vol. 11, 1993, pages 643-649, XP002137199<br>BUTTERWORTH SCIENTIFIC. GUILDFORD., GB<br>ISSN: 0264-410X<br>the whole document<br>----- | 1-43,45               |
| P,X  | J.B. DALE ET AL: "New protective antigen<br>of group A Streptococci"<br>THE JOURNAL OF CLINICAL INVESTIGATION ,<br>vol. 103, no. 9, May 1999 (1999-05), pages<br>1261-1268, XP000906814<br>the whole document<br>-----   | 1-43,45               |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 30807

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 41-43, 45  
are directed to a method of treatment of the human/animal  
body (rule 39.1 IV PCT, the search has been carried out and based  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/30807

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s)                   | Publication<br>date                    |
|---|---------------------|--|--|
| WO 9801561 A                              | 15-01-1998          | IE 960488 A<br>AU 3187797 A                  | 19-11-1997<br>02-02-1998               |
| WO 9406421 A                              | 31-03-1994          | AU 5128493 A<br>CA 2123579 A<br>EP 0625043 A | 12-04-1994<br>31-03-1994<br>23-11-1994 |
| WO 9406465 A                              | 31-03-1994          | AU 5128593 A<br>CA 2123580 A<br>EP 0618813 A | 12-04-1994<br>21-03-1994<br>12-10-1994 |

**THIS PAGE BLANK (USPTO)**